<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0602244856
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Eylea
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AFLIBERCEPT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        114.3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravitreal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3028.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CATALENT" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CATALENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2947]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Bayer Saudi Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01LA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Eylea is</strong></p><p>Eylea contains the active substance aflibercept. It belongs to a group of medicines called antineovascularistion agents.</p><p>&nbsp;</p><p>Your doctor will inject Eylea into your eye to treat eye disorders in adults called:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wet age‑related macular degeneration (wet AMD)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual impairment due to diabetic macular oedema (DME).</p><p>&nbsp;</p><p>These disorders affect the macula. The macula is the central part of the light sensitive membrane at the back of the eye. It is responsible for clear vision.</p><p>Wet AMD is caused when abnormal blood vessels form and grow below the macula. The abnormal blood vessels may leak fluid or blood into the eye. Leaky blood vessels that cause swelling of the macula cause DME. Both disorders may impact your vision.</p><p>&nbsp;</p><p><strong>How Eylea works</strong></p><p>Eylea stops growth of new abnormal blood vessels in the eye. Eylea can help to stabilise and often improve vision.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You will not receive Eylea if you</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to aflibercept or any of the other ingredients of this medicine (listed in section&nbsp;6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an infection in or around the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have pain or redness in your eye (severe eye inflammation).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor <strong>before receiving</strong> Eylea if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have glaucoma &ndash; an eye condition caused by high pressure in the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of seeing flashes of light or dark floating spots and if their size or number suddenly increases</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; had eye surgery in the last 4&nbsp;weeks or eye surgery is planned in the next 4&nbsp;weeks.</p><p>&nbsp;</p><p>Tell your doctor <strong>immediately if </strong>you develop:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased discomfort</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred or decreased vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sensitivity to light</p><p>These may be symptoms of an inflammation or infection and your doctor may stop giving you Eylea.</p><p><strong>&nbsp;</strong></p><p>Furthermore, it is important for you to know that:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the safety and efficacy of Eylea when administered to both eyes at the same time have not been studied and such use may increase risk of experiencing side effects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injections with Eylea may cause an increase in eye pressure in some patients within 60&nbsp;minutes of the injection. Your doctor will monitor this after each injection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your doctor will check for other risk factors that may increase the chance of a tear or detachment of one of the layers at the back of the eye. In such cases your doctor will give you Eylea with caution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; women who could become pregnant must use effective birth control during treatment and for at least 4 months after the last injection of Eylea.</p><p>&nbsp;</p><p>The use of substances similar to those contained in Eylea is potentially related to the risk of blood clots blocking blood vessels, which may lead to heart attack or stroke. Theoretically, this could also happen after an injection of Eylea into the eye. If you had a stroke, a mini-stroke or a heart attack within the last 6 months, your doctor will give you Eylea with caution.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The use of Eylea in children or adolescents under 18 has not been studied because the diseases indicated occur mainly in adults. Therefore, its use in this age group is not relevant.</p><p>&nbsp;</p><p><strong>Other medicines and Eylea</strong></p><p>Tell your doctor if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Women who could become pregnant must use effective birth control during treatment and for at least 4&nbsp;months after the last injection of Eylea.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is no experience on the use of Eylea in pregnant women. Women should not receive Eylea during pregnancy unless the potential benefit to the woman outweighs the potential risk to the unborn child.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Small amounts of Eylea may pass into human milk. The effect on breast‑fed newborns/infants are unknown. Eylea is not recommended during breast‑feeding.</p><p>Therefore, if you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you receive this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>After receiving Eylea, you may experience some temporary vision problems. Do not drive or use machines as long as these last.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The recommended dose is 8&nbsp;mg aflibercept per injection.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will receive 1&nbsp;injection every month for the first 3&nbsp;months.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After that, you may receive injections up to every 5&nbsp;months. Your doctor will decide on the frequency based on the condition of your eye.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>Your doctor will inject Eylea into your eye (intravitreal injection).</p><p>&nbsp;</p><p>Before the injection, your doctor will use a disinfectant eyewash to clean your eye carefully to prevent infection. Your doctor will give you an eye drop (local anaesthetic) to numb the eye to reduce or prevent pain from the injection.</p><p><em>&nbsp;</em></p><p><strong>If you missed a dose of Eylea</strong></p><p>Make a new appointment with your doctor as soon as possible.</p><p>&nbsp;</p><p><strong>Before stopping Eylea treatment</strong></p><p>Speak with your doctor before stopping treatment. Stopping treatment may increase your risk of vision loss and your vision may worsen.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The side effects of Eylea injection are either from the medicine itself or from the injection procedure and mostly affect the eye.</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects could be serious</strong></p><p>Contact your doctor immediately if you have any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common side effect, which may affect up to&nbsp;1 in 10&nbsp;people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clouding of the lens (cataract)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the back of the eye (retinal haemorrhage)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of pressure inside the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding inside the eye (vitreous haemorrhage)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncommon side effect, which may affect up to&nbsp;1 in 100&nbsp;people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain forms of clouding of the lens (cataract subcapsular)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; detachment, tear or bleeding of the light-sensitive layer at the back of the eye, resulting in flashes of light with floaters, sometimes progressing to a loss of vision (retinal detachment or tear)</p><p>&nbsp;</p><p><strong>Other possible side effects</strong></p><p><strong>Common</strong> (may affect up to 1 in 10&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moving spot in your vision (vitreous floaters)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; detachment of the gel‑like substance inside the eye (vitreous detachment)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced sharpness of vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding inside the eye (conjunctival haemorrhage)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to the clear layer of the eyeball in front of the iris (punctate keratitis)</p><p><strong>Uncommon</strong> (may affect up to 1 in 100&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; detachment or tear of one of the layers in the back of the eye, resulting in flashes of light with floaters, sometimes progressing to a loss of vision (retinal pigment epithelial tear/detachment;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation in the iris, of other parts of the eye, or the gel‑like substance inside the eye (iritis, iridocyclitis, vitritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain forms of clouding of the lens (cataract cortical/nuclear)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to the front layer of the eyeball (corneal abrasion/erosion)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye pain at injection site</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a feeling of having something in the eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased tear production</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding at the injection site</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the eye</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1&nbsp;000&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blindness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of other parts of the eye (uveitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the eyelid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritation at injection site</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the front layer of the eyeball (corneal oedema)</p><p>&nbsp;</p><p>Besides the above the following side effects may occur although they have not been reported in clinical studies:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the eye (ocular hyperaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; degeneration of the light sensitive membrane at the back of the eye (retinal degeneration)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal sensation in eye</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clouding of the lens (lenticular opacities), clouding of the lens due to injury (traumatic cataract)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to the surface of the clear front layer of the eye (corneal epithelium defect)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of other parts of the eye (anterior chamber flare)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eyelid irritation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious inflammation or infection inside the eye (endophthalmitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pus in the eye (hypopyon)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>Other Countries:</strong></p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&nbsp;&deg;C&nbsp;&ndash;&nbsp;8&nbsp;&deg;C). Do not freeze.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the vial in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Eylea contains </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is aflibercept. 1&nbsp;ml solution contains 114.3&nbsp;mg aflibercept. Each vial contains 0.263&nbsp;ml. This provides a usable amount to deliver a single dose of 0.07&nbsp;ml containing 8&nbsp;mg aflibercept.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: sucrose, arginine hydrochloride, histidine hydrochloride monohydrate, histidine, polysorbate&nbsp;20, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Eylea looks like and contents of the pack
	Eylea is a solution for injection (injection). The solution is colourless to pale yellow.
	Pack size: 1 vial + 1 filter needle.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Bulk manufacturer</strong></p><p>Catalent Indiana, LLC</p><p>1300 South Patterson Drive,</p><p>Bloomington, IN 47403, USA.</p><p><strong>Final Release </strong></p><p>Bayer AG</p><p>M&uuml;llerstra&szlig;e 178</p><p>13353 Berlin, Germany.</p><p><strong>Marketing Authorisation Holder</strong></p><p>Bayer AG</p><p>Kaiser-Wilhelm-Allee 1</p><p>51368 Leverkusen, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in January 2024.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هو أيليا</p><p dir="RTL">يحتوي أيليا على المادة الفعالة أفليبرسبت. إنه ينتمي إلى مجموعة من الأدوية تسمى مضادات الأوعية الدموية.</p><p dir="RTL">سيحقن طبيبك أيليا في عينك لعلاج اضطرابات العين لدى البالغين المسماة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; انحلال البقعة الصفراء الرطب المرتبط بالسن (Wet AMD).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ضعف الرؤية بسبب وذمة البقعة الصفراء ( الشبكية ) نتيجة داء السكري (DME).</p><p dir="RTL">تؤثر هذه الاضطرابات على البقعة الصفراء .البقعة الصفراء هي الجزء المركزي من الغشاء الحساس للضوء في مؤخرة العين. إنها مسؤولة عن وضوح الرؤية.</p><p dir="RTL">يحدث انحلال البقعة الصفراء الرطب المرتبط بالسن عندما تتشكل الأوعية الدموية غير الطبيعية وتنمو أسفل البقعة الصفراء. قد تتسرب السوائل او الدم من الاوعية الدموية غير الطبيعيه الى العين. الأوعية الدموية المتسربة التي تسبب تورم البقعة الصفراء ، تسبب الوذمة البقعية السكرية. قد يؤثر كلا الاضطرابين على رؤيتك.</p><p dir="RTL">&nbsp;</p><p>كيف يعمل أيليا</p><p dir="RTL">يوقف أيليا نمو الأوعية الدموية الجديدة غير الطبيعية في العين. يمكن أن يساعد أيليا في استقرار الرؤية وتحسينها في كثير من الأحيان.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لن تتلقى أيليا إذا كنت</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لديك حساسية من أفليبرسبت أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لديك عدوى في العين أو حولها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لديك ألم أو احمرار في عينك (التهاب شديد في العين)</p><p dir="RTL">&nbsp;</p><p>المحاذير والإحتياطات</p><p dir="RTL">تحدث إلى طبيبك <strong>قبل تلقي</strong> أيليا إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لديك الجلوكوما - حالة في العين ناتجة عن ارتفاع ضغط في العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لديك تاريخ في رؤية ومضات من الضوء أو البقع العائمة المظلمة وإذا زاد حجمها أو عددها فجأة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; خضعت لعملية جراحية في العيون خلال الأسابيع الأربعة الماضية أو من المقرر إجراء عملية جراحية في العيون في الأسابيع الأربعة القادمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك <strong>على الفور إذا</strong> ظهرت عليك الأعراض التالية:</p><p dir="RTL">-&nbsp; احمرار العين</p><p dir="RTL">-&nbsp; ألم في العين</p><p dir="RTL">-&nbsp; زيادة عدم الشعور بالراحة</p><p dir="RTL">-&nbsp; عدم وضوح الرؤية أو ضعفها</p><p dir="RTL">-&nbsp; زيادة الحساسية للضوء</p><p dir="RTL">قد تكون هذه أعراض التهاب أو عدوى وقد يوقف طبيبك عن إعطائك أيليا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">علاوة على ذلك، من المهم أن تعرف ما يلي:</p><p dir="RTL">-&nbsp; لم يتم دراسة سلامة وفعالية أيليا عند إعطائه لكلتا العينين في الوقت نفسه، وقد يؤدي استخدامه بهذه الطريقة إلى زيادة خطر التعرض لآثار جانبية.</p><p dir="RTL">-&nbsp; قد يؤدي الحقن بأيليا إلى زيادة ضغط العين لدى بعض المرضى خلال 60 دقيقة من الحقن. سيراقب طبيبك هذا بعد كل حقنة.</p><p dir="RTL">-&nbsp; سيتحقق طبيبك من وجود عوامل خطر أخرى قد تزيد من فرصة حدوث تمزق أو انفصال إحدى الطبقات الموجودة في الجزء الخلفي من العين. في حالات كهذه، سوف يعطيك طبيبك أيليا بحذر.</p><p dir="RTL">-&nbsp; يجب على النساء اللاتي يمكن أن يحملن أن يستخدمن وسائل منع الحمل الفعالة أثناء العلاج ولمدة 4 أشهر على الأقل بعد الحقنة الأخيرة من أيليا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المحتمل أن يكون استخدام مواد مشابهة لتلك الموجودة في أيليا مرتبطًا بخطر حدوث جلطات دموية تسد الأوعية الدموية، ما قد يؤدي إلى نوبة قلبية أو سكتة دماغية. نظرياً، يمكن أن يحدث هذا أيضًا بعد حقن أيليا في العين. إذا تعرضت لسكتة دماغية، سكتة دماغية صغيرة أو نوبة قلبية خلال الأشهر الستة الماضية، فسوف يعطيك طبيبك أيليا بحذر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ا</strong><strong>لأطفال والمراهقون</strong></p><p dir="RTL">لم يتم دراسة استخدام أيليا في الأطفال أو المراهقين الذين تقل أعمارهم عن 18 عامًا لأن الأمراض المشار إليها تحدث بشكل رئيسي عند البالغين. لذلك، فإن استخدامه في هذه الفئة العمرية غير مناسب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى و أيليا</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يجب على النساء اللواتي قد يحملن استخدام وسيلة فعالة لمنع الحمل أثناء العلاج ولمدة 4 أشهر على الأقل بعد الحقن الأخير من أيليا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لا توجد معلومات حول استخدام أيليا من قبل النساء الحوامل. يجب ألا تتلقى النساء أيليا أثناء الحمل إلا إذا كانت الفائدة المحتملة للمرأة تفوق المخاطر المحتملة على الجنين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; قد تنتقل كميات قليلة من أيليا إلى حليب الأم. التأثير على الأطفال حديثي الولادة / الرضع الذين يرضعون من الثدي غير معروف. لا ينصح باستخدام أيليا أثناء الرضاعة الطبيعية.</p><p dir="RTL">لذلك، إذا كنت حاملًا أو مرضعة، أو تعتقدين أنك حاملًا أو تخططين لإنجاب طفل، استشيري طبيبك قبل تلقي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل</strong><strong> الماكينات</strong></p><p dir="RTL">بعد تلقيك أيليا، قد تواجه بعض المشكلات المؤقتة في الرؤية. لا تقود السيارة أو تستخدم الآلات ما دامت هذه المشكلات مستمرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة الموصى بها هي 8 مجم من الأفليبرسبت&nbsp; لكل حقنة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; سوف تتلقى حقنة واحدة كل شهر لمدة الـ 3 أشهر الأولى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; بعد ذلك،&nbsp; قد تتلقى حقنًا كل 5 أشهر. سيقرر طبيبك عدد مرات التكرار بناءً على حالة عينك.</p><p>&nbsp;</p><p>طريقة الإعطاء</p><p dir="RTL">سيقوم طبيبك بحقن أيليا في عينك (الحقن داخل الجسم الزجاجي).</p><p dir="RTL">قبل الحقن، سيستخدم طبيبك غسولًا مطهرًا للعين لتنظيف عينك بعناية لمنع العدوى. سيعطيك طبيبك قطرة للعين (مخدر موضعي) لتخدير العين لتقليل أو منع الألم جراء الحقن.</p><p>&nbsp;</p><p>إذا فاتتك جرعة من أيليا</p><p dir="RTL">حدد موعدًا جديدًا مع طبيبك في أسرع وقت ممكن.</p><p>&nbsp;</p><p>قبل التوقف عن علاج أيليا</p><p dir="RTL">تحدث مع طبيبك قبل التوقف عن العلاج. قد يؤدي إيقاف العلاج إلى زيادة خطر الإصابة بفقدان البصر وقد تسوء رؤيتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">الآثار الجانبية لحقن أيليا إما بسبب الدواء نفسه أو بسبب إجراء الحقن و في الغالب تؤثر على العين.</p><p dir="RTL">&nbsp;</p><p>قد تكون بعض الآثار الجانبية خطيرة</p><p dir="RTL">اتصل بطبيبك على الفور إذا كان لديك أي مما يلي:</p><p dir="RTL"><strong>آثار جانبية شائعة</strong> (قد تظهر لدى حتى 1 من كل 10 أشخاص):</p><p dir="RTL">-&nbsp; تغيم العدسة (إعتام عدسة العين)</p><p dir="RTL">-&nbsp; نزيف في الجزء الخلفي من العين (نزيف في الشبكية)</p><p dir="RTL">-&nbsp; زيادة الضغط داخل العين</p><p dir="RTL">-&nbsp; نزف داخل العين (نزيف في الجسم الزجاجي)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong><strong> </strong>(قد تظهر لدى حتى 1 من كل 100 شخص):</p><p dir="RTL">-&nbsp; أشكال معينة من ضبابية العدسة (الساد تحت المحفظة)</p><p dir="RTL">-&nbsp; انفصال، تمزق، أو نزيف في الطبقة الحساسة للضوء في الجزء الخلفي من العين، مما يؤدي إلى ظهور ومضات من الضوء مع وجود عوائم تتطور أحيانًا إلى فقدان الرؤية &nbsp;(انفصال الشبكية أو تمزقها)</p><p dir="RTL">&nbsp;</p><p>الآثار الجانبية المحتملة الأخرى</p><p dir="RTL"><strong>شائعة</strong> (قد تظهر لدى حتى 1 من كل 10 أشخاص):</p><p dir="RTL">-&nbsp; بقعة متحركة في رؤيتك (عوائم زجاجية)</p><p dir="RTL">-&nbsp; انفصال المادة الهلامية داخل العين (انفصال الجسم الزجاجي)</p><p dir="RTL">-&nbsp; انخفاض حدة الرؤية</p><p dir="RTL">-&nbsp; ألم في العين</p><p dir="RTL">-&nbsp; نزيف داخل العين (نزيف الملتحمة)</p><p dir="RTL">-&nbsp; تلف الطبقة الشفافة لمقلة العين أمام القزحية (التهاب القرنية)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة</strong><strong> </strong>(قد تظهر لدى حتى 1 من كل 100 شخص):</p><p dir="RTL">-&nbsp; ردود الفعل التحسسية</p><p dir="RTL">-&nbsp; انفصال أو تمزق إحدى الطبقات الموجودة في الجزء الخلفي من العين، مما يؤدي إلى ظهور ومضات من الضوء مع وجود عوائم تتطور أحيانًا إلى فقدان الرؤية (تمزق / انفصال صباغ النسيج الغشائي الخلوي)</p><p dir="RTL">-&nbsp; التهاب في القزحية أو في أجزاء أخرى من العين أو المادة المشابهة للهلام داخل العين (التهاب القزحية، التهاب القزحية الهدبية، التهاب الزجاجية).</p><p dir="RTL">-&nbsp; بعض أشكال عتامة العدسة (إعتام عدسة العين القشرية (كاتاراكت)/ النواة)</p><p dir="RTL">-&nbsp; تلف الطبقة الأمامية من مقلة العين (تآكل / خدش القرنية)</p><p dir="RTL">-&nbsp; عدم وضوح الرؤية</p><p dir="RTL">-&nbsp; ألم في العين في موقع الحقن</p><p dir="RTL">-&nbsp; شعور بوجود شيء في العين</p><p dir="RTL">-&nbsp; زيادة إنتاج الدموع</p><p dir="RTL">-&nbsp; نزف في موقع الحقن</p><p dir="RTL">-&nbsp; احمرار العين</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة</strong> (قد تؤثر على حتى 1 من كل 1000 شخص):</p><p dir="RTL">-&nbsp; عمى</p><p dir="RTL">-&nbsp; التهاب أجزاء أخرى من العين (التهاب القزحية)</p><p dir="RTL">-&nbsp; تورم الجفن</p><p dir="RTL">-&nbsp; تهيج في موقع الحقن</p><p dir="RTL">-&nbsp; تورم الطبقة الأمامية لمقلة العين (وذمة القرنية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إلى جانب ما سبق، قد تحدث الآثار الجانبية التالية على الرغم من أنها لم يتم الإبلاغ عنها في الدراسات السريرية:</p><p dir="RTL">-&nbsp; احمرار العين (احتقان العين)،</p><p dir="RTL">-&nbsp; تنكس الغشاء الحساس للضوء في مؤخرة العين (انحلال الشبكية)،</p><p dir="RTL">-&nbsp; إحساس غير طبيعي في العين،</p><p dir="RTL">-&nbsp; ضبابية في العدسة (عتامة عدسية)،</p><p dir="RTL">-&nbsp; الضبابية في العدسة بسبب الإصابة (إعتام عدسة العين)،</p><p dir="RTL">-&nbsp; تلف سطح مقدمة العين الواضحة (عيب في ظهارة القرنية)،</p><p dir="RTL">-&nbsp; التهاب في أجزاء أخرى من العين (توهج الغرفة الأمامية)،</p><p dir="RTL">-&nbsp; تهيج الجفن،</p><p dir="RTL">-&nbsp; التهاب أو عدوى خطيرة داخل العين (التهاب باطن المقلة)،</p><p dir="RTL">-&nbsp; صديد في العين (قصور)،</p><p dir="RTL">-&nbsp; تفاعلات حساسية شديدة.</p><p dir="RTL">&nbsp;</p><p>الإبلاغ عن الأعراض الجانبية</p><p dir="RTL">إذا كنت تعاني من أي آثار جانبية، تحدث إلى طبيبك. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL"><strong>السعودية:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa<strong> </strong></p><p dir="RTL"><strong>بلدان أخرى:</strong></p><p dir="RTL">يرجى الاتصال بالسلطة المختصة ذات الصلة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والملصق بعد انتهاء الصلاحية. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر نفسه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في الثلاجة (2 درجة مئوية - 8 درجة مئوية). لا يجمد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بالعبوة الزجاجية في العبوة الكرتونية الخارجية لحمايتها من الضوء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اذا تحتوي أيليا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي أفليبرسبت. 1 مل من المحلول يحتوي على 114.3 مجم أفليبرسبت. تحتوي كل قنينة على 0.263 مل. توفر هذه كمية قابلة للاستخدام لتوصيل جرعة واحدة من 0.07 مل تحتوي على 8 مجم أفليبرسبت.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: سكروز، وأرجينين هيدروكلوريد، وهيستيدين هيدروكلوريد مونوهيدرات، وهيستيدين، وبولي سوربات 20، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو أيليا ومحتويات العبوة</p><p dir="RTL">أيليا هو محلول للحقن (الحقن). المحلول عديم اللون مائل إلى الأصفر الباهت.</p><p dir="RTL">حجم العبوة: 1 عبوة زجاجية + 1 إبرة ترشيح.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">كاتالنت إنديانا، ال ال سي</p><p dir="RTL">1300 ساوث باترسون درايف،</p><p dir="RTL">بلومنجتون، IN 47403، الولايات المتحدة الأمريكية.</p><p dir="RTL"><strong>الإفراج النهائي</strong></p><p dir="RTL">باير ايه جي</p><p dir="RTL">178 مولر شتراس</p><p dir="RTL">13353 برلين، ألمانيا</p><p dir="RTL"><strong>حامل ترخيص التسويق:</strong></p><p dir="RTL">باير ايه جي</p><p dir="RTL">قيصر-ويلهلم-آلي 1،</p><p dir="RTL">51368 ليفركوزن، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في  يناير 2024.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eylea 114.3 mg/ml solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml solution for injection contains 114.3 mg aflibercept*.

Each vial contains 30.1 mg aflibercept in 0.263 ml solution. This provides a usable amount to deliver a single dose of 0.07 ml containing 8 mg aflibercept.

* Aflibercept is a fusion protein consisting of portions of human VEGF (vascular endothelial growth factor) receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)
Clear to slightly opalescent, colourless to pale yellow, iso osmotic solution, pH 5.8.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Eylea is indicated in adults for the treatment of</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neovascular (wet) age‑related macular degeneration (nAMD) (see section&nbsp;5.1)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual impairment due to diabetic macular oedema (DME) (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Eylea must only be administered by a qualified physician experienced in intravitreal injections.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose is 8&nbsp;mg aflibercept, equivalent to 0.07&nbsp;ml solution. The posology is the same for the nAMD and DME indications. The 8&nbsp;mg dose requires use of the Eylea&nbsp;114.3&nbsp;mg/ml vial.</p><p>&nbsp;</p><p>Eylea treatment is initiated with 1&nbsp;injection per month for 3&nbsp;consecutive doses. Injection intervals may then be extended up to every 4&nbsp;months based on the physician&rsquo;s judgement of visual and/or anatomic outcomes. Subsequently, the treatment intervals may be further extended up to 5&nbsp;months, such as with a treat‑and‑extend dosing regimen, while maintaining stable visual and/or anatomic outcomes (see section&nbsp;5.1).</p><p>&nbsp;</p><p>If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly based on the physician&rsquo;s discretion. The shortest interval between 2&nbsp;injections is 2&nbsp;months in the maintenance phase.</p><p>&nbsp;</p><p>Eylea at monthly doses of 8&nbsp;mg has not been studied for more than 3&nbsp;consecutive doses.</p><p>&nbsp;</p><p>The frequency of monitoring visits should be based on the patient&rsquo;s status and at the physician&rsquo;s discretion. For events in which treatment should be withheld see section&nbsp;4.4.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal or hepatic impairment</em></p><p>No specific studies in patients with renal or hepatic impairment have been conducted.</p><p>Available data do not suggest a need for a dose adjustment with Eylea in these patients (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Available data do not suggest a need for a dose adjustment with Eylea in these patients.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Eylea 114.3&nbsp;mg/ml in children and adolescents below 18&nbsp;years have not been established. There is no relevant use of Eylea 114.3&nbsp;mg/ml in the paediatric population in the nAMD and DME indications.</p><p><u>&nbsp;</u></p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>Eylea is for intravitreal injection only.</p><p>&nbsp;</p><p>Intravitreal injections must be carried out according to medical standards and applicable guidelines by a qualified physician experienced in administering intravitreal injections. In general, adequate anaesthesia and asepsis, including topical broad spectrum microbicide (e.g. povidone iodine applied to the periocular skin, eyelid and ocular surface), have to be ensured. Surgical hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent) are recommended.</p><p>&nbsp;</p><p>The injection needle should be inserted 3.5&nbsp;to&nbsp;4.0&nbsp;mm posterior to the limbus into the vitreous cavity, avoiding the horizontal meridian and aiming towards the centre of the globe. The injection volume of 0.07&nbsp;ml is then delivered. A different scleral site should be used for subsequent injections.</p><p>&nbsp;</p><p>Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, sterile equipment for paracentesis should be available.</p><p>&nbsp;</p><p>Following intravitreal injection, patients should be instructed to report any symptoms suggestive of endophthalmitis (e.g. eye pain, redness of the eye, photophobia, blurring of vision) without delay.</p><p>&nbsp;</p><p>Each vial should only be used for the treatment of a single eye.</p><p>After injection, discard any unused product or waste material in accordance with local requirements.</p><p>&nbsp;</p><p>For handling of the medicinal product before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	Ocular or periocular infection.
-	Active severe intraocular inflammation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Intravitreal injection‑related reactions </u></p><p>&nbsp;</p><p>Intravitreal injections, including those with Eylea, have been associated with endophthalmitis, intraocular inflammation, retinal detachment, retinal tear and traumatic cataract (see section&nbsp;4.8). Proper aseptic injection techniques must always be used when administering Eylea. Patients should be instructed to report any symptoms suggestive of endophthalmitis or any of the above mentioned events without delay and should be managed appropriately.<em> </em></p><p><u>&nbsp;</u></p><p><u>Intraocular pressure increased </u></p><p>&nbsp;</p><p>Transient increases in intraocular pressure have been seen within 60&nbsp;minutes of an intravitreal injection, including those with Eylea (see section&nbsp;4.8). Both the intraocular pressure and perfusion of the optic nerve head must therefore be monitored and managed appropriately. Special precaution is needed in patients with poorly controlled glaucoma (do not inject Eylea while the intraocular pressure is &ge;&nbsp;30&nbsp;mmHg).</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>As this is a therapeutic protein, there is a potential for immunogenicity with aflibercept (see section&nbsp;5.1). Patients should be instructed to report any signs or symptoms of intraocular inflammation, e.g. pain, photophobia, or redness, which may be a clinical sign attributable to hypersensitivity.</p><p>&nbsp;</p><p><u>Systemic effects</u></p><p>&nbsp;</p><p>Systemic adverse events including non‑ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors and there is a theoretical risk that these may relate to VEGF inhibition (see section&nbsp;4.8).</p><p>There are limited data on safety in the treatment of patients with nAMD and DME with a history of stroke, transient ischaemic attacks or myocardial infarction within the last 6&nbsp;months. Caution should be exercised when treating such patients.</p><p>&nbsp;</p><p><u>Bilateral treatment</u></p><p>&nbsp;</p><p>The safety and efficacy of bilateral treatment with Eylea&nbsp;114.3&nbsp;mg/ml per eye have not been studied (see section&nbsp;5.1). If bilateral treatment is performed at the same time this could lead to an increased systemic exposure, which could increase the risk of systemic adverse events.</p><p>&nbsp;</p><p><u>Concomitant use of other anti-VEGF</u></p><p>&nbsp;</p><p>There are limited data available on the concomitant use of Eylea with other anti‑VEGF medicinal products (systemic or ocular).</p><p>&nbsp;</p><p><u>Withholding treatment</u></p><p>&nbsp;</p><p>Treatment should be withheld in the event of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease in best corrected visual acuity (BCVA) of &ge;&nbsp;30 letters compared with the last assessment of visual acuity</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rhegmatogenous retinal detachment or stage&nbsp;3 or&nbsp;4 macular holes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a retinal break</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a subretinal haemorrhage involving the centre of the fovea, or, if the size of the haemorrhage is &ge;&nbsp;50&nbsp;% of the total lesion area</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; performed or planned intraocular surgery within the previous or next 28&nbsp;days.</p><p>&nbsp;</p><p><u>Retinal pigment epithelial tear</u></p><p>&nbsp;</p><p>Risk factors associated with the development of a retinal pigment epithelial tear after anti‑VEGF therapy for nAMD include a large and/or high pigment epithelial retinal detachment. When initiating aflibercept therapy, caution should be used in patients with these risk factors for retinal pigment epithelial tears.</p><p>&nbsp;</p><p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of childbearing potential have to use effective contraception during treatment and for at least 4&nbsp;months after the last intravitreal injection with Eylea&nbsp;114.3&nbsp;mg/ml (See section&nbsp;4.6).</p><p>&nbsp;</p><p><u>Populations with limited data</u></p><p>&nbsp;</p><p>There is only limited experience with Eylea treatment in diabetic patients with an HbA1c over 12&nbsp;% or with proliferative diabetic retinopathy.</p><p>Eylea has not been studied in patients with active systemic infections or in patients with concurrent eye conditions such as retinal detachment or macular hole. There is also no experience of treatment with Eylea in diabetic patients with uncontrolled hypertension. This lack of information should be considered by the physician when treating such patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of childbearing potential have to use effective contraception during treatment and for at least 4&nbsp;months after the last intravitreal injection with Eylea&nbsp;114.3&nbsp;mg/ml.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are limited data on the use of aflibercept in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section&nbsp;5.3).</p><p>Eylea&nbsp;114.3&nbsp;mg/ml should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Based on very limited human data, aflibercept may be excreted in human milk at low levels. Aflibercept is a large protein molecule and the amount of medication absorbed by the infant is expected to be minimal. The effect of aflibercept on a breast-fed newborn/infant is unknown.</p><p>As a precautionary measure breast‑feeding is not recommended during the use of Eylea&nbsp;114.3&nbsp;mg/ml.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no fertility data in humans. Results from animal studies with high systemic exposure indicate that aflibercept can impair male and female fertility (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Injection with Eylea has minor influence on the ability to drive and use machines due to possible temporary visual disturbance associated either with the injection or eye examination. Patients should not drive or use machines until their visual function has recovered sufficiently.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>Serious adverse reactions were cataract (4.0%), retinal haemorrhage (2.6%), intraocular pressure increased (2.4%), vitreous haemorrhage (1.0%), cataract subcapsular (0.5%), retinal detachment (0.4%), and retinal tear (0.3%).</p><p>&nbsp;</p><p>The most frequently observed adverse reactions in patients treated with Eylea&nbsp;114.3&nbsp;mg/ml were cataract (4.0%), vitreous floaters (3.5%), visual acuity reduced (3.2%), conjunctival haemorrhage (3.1%), vitreous detachment (2.9%), retinal haemorrhage (2.6%), and intraocular pressure increased (2.4%).</p><p>&nbsp;</p><p>The safety profile observed in the 3&nbsp;clinical studies was similar in patients treated with Eylea&nbsp;114.3&nbsp;mg/ml (N=1&nbsp;217) and Eylea&nbsp;40&nbsp;mg/ml (N=556), and in patients with nAMD and DME.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>A total of 1&nbsp;217&nbsp;patients treated with Eylea&nbsp;114.3&nbsp;mg/ml constituted the safety population in 3&nbsp;clinical phase&nbsp;II/III studies (CANDELA, PULSAR, PHOTON).</p><p>The safety data described below include all adverse reactions with a reasonable possibility of causality to the injection procedure or medicinal product reported&nbsp;&nbsp;&nbsp; .</p><p>&nbsp;</p><p>The adverse reactions are listed by system organ class and frequency using the following convention: Very common (&ge;1/10), common (&ge;1/100&nbsp;to&nbsp;&lt;1/10), uncommon (&ge;1/1&nbsp;000&nbsp;to&nbsp;&lt;1/100), rare (&ge;1/10&nbsp;000&nbsp;to&nbsp;&lt;1/1&nbsp;000).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table&nbsp;1: All treatment‑emergent adverse reactions reported in patients with nAMD or DME treated with Eylea&nbsp;114.3&nbsp;mg/ml in phase&nbsp;II/III studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Cataract,</p><p>Intraocular pressure increased,</p><p>Vitreous floaters,</p><p>Vitreous detachment,</p><p>Vitreous haemorrhage,</p><p>Retinal haemorrhage,</p><p>Visual acuity reduced,</p><p>Eye pain,</p><p>Conjunctival haemorrhage,</p><p>Punctate keratitis</p></td><td style="vertical-align:top"><p>Retinal detachment,</p><p>Retinal tear,</p><p>Retinal pigment epithelial tear,</p><p>Detachment of the retinal pigment epithelium,</p><p>Iritis,</p><p>Iridocyclitis,</p><p>Vitritis,</p><p>Cataract cortical,</p><p>Cataract nuclear,</p><p>Cataract subcapsular,</p><p>Corneal erosion,</p><p>Corneal abrasion,</p><p>Vision blurred,</p><p>Injection site pain,</p><p>Foreign body sensation in eyes,</p><p>Lacrimation increased,</p><p>Injection site haemorrhage,</p><p>Conjunctival hyperaemia</p></td><td style="vertical-align:top"><p>Blindness,</p><p>Uveitis,</p><p>Eyelid oedema,</p><p>Injection site irritation,</p><p>Corneal oedema</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reports of hypersensitivity included rash, pruritus, urticaria.</p><p><u>&nbsp;</u></p><p>The following adverse reactions of Eylea&nbsp;40&nbsp;mg/ml are also considered expected with Eylea&nbsp;114.3&nbsp;mg/ml but have not been reported in the clinical studies with Eylea&nbsp;114.3&nbsp;mg/ml: ocular hyperaemia, retinal degeneration, abnormal sensation in eye, lenticular opacities, corneal epithelium defect, anterior chamber flare, eyelid irritation, endophthalmitis, traumatic cataract, hypopyon, severe anaphylactic/anaphylactoid reactions.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Product‑class‑related adverse reactions</em></p><p>Arterial thromboembolic events (ATEs) are adverse reactions potentially related to systemic VEGF inhibition. There is a theoretical risk of ATEs, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of ATEs was observed in the aflibercept clinical studies in patients with nAMD and DME. Across indications, no notable difference between the groups treated with Eylea&nbsp;114.3&nbsp;mg/ml and the comparator groups treated with Eylea&nbsp;40&nbsp;mg/ml were observed.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>Other Countries:</strong></p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdosing with increased injection volume may increase intraocular pressure. Therefore, in case of overdose, intraocular pressure should be monitored and, if deemed necessary by the treating physician, adequate treatment should be initiated (see sections&nbsp;4.4 and&nbsp;6.6).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Ophthalmologicals / Antineovascularisation agents, ATC code:&nbsp;S01LA05</p><p>&nbsp;</p><p>Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptor&nbsp;1 and&nbsp;2 extracellular domains fused to the Fc portion of human IgG1.</p><p>&nbsp;</p><p>Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Vascular endothelial growth factor‑A (VEGF‑A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as potent mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR‑1 and VEGFR‑2, present on the surface of endothelial cells. PlGF binds only to VEGFR‑1, which is also present on the surface of leucocytes. Excessive activation of these receptors by VEGF‑A can result in pathological neovascularisation and excessive vascular permeability. PlGF can act independently to activate the VEGFR‑1 to promote an inflammatory response within the retina, and is known to increase in pathological states such as nAMD, diabetic retinopathy (DR), DME, and retinal vein occlusion (RVO).</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Aflibercept acts as a soluble decoy receptor that binds VEGF‑A and PlGF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors.</p><p>In animal studies, aflibercept can prevent pathological neovascularization and vascular leakage in a number of different models of ocular disease.</p><p>&nbsp;</p><p><em><u>nAMD</u></em></p><p><em>&nbsp;</em></p><p>nAMD is characterised by pathological choroidal neovascularisation (CNV). Leakage of blood and fluid from CNV may cause retinal oedema and/or sub‑/intra‑retinal haemorrhage, resulting in loss of visual acuity.</p><p>&nbsp;</p><p>The pharmacodynamic effects of aflibercept 114.3&nbsp;mg/ml administered every 12 (8Q12) and every 16 (8Q16) weeks are described in comparison with aflibercept 40 mg/ml administered every 8&nbsp;weeks (2Q8) for the nAMD indication. These effects are shown as the change in CNV size from baseline to week 12; change in total lesion area from baseline to weeks&nbsp;48 and 60; and change from baseline in central retinal thickness (CRT).</p><p>&nbsp;</p><p>In the pooled group of patients treated with 8Q12 or 8Q16, reductions in CNV size (LS mean, based on a mixed model for repeated measurements [MMRM]) at week&nbsp;12 were ‑1.63&nbsp;mm<sup>2</sup> compared to ‑1.17&nbsp;mm<sup>2</sup> for patients treated with 2Q8.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;2: Pharmacodynamic parameter (full analysis set) in the PULSAR study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td><p><strong>Efficacy outcomes</strong></p></td><td><p><strong>Week</strong></p></td><td><p><strong>Eylea 8Q12</strong></p><p><strong>(N&nbsp;=&nbsp;335)</strong></p></td><td><p><strong>Eylea 8Q16</strong></p><p><strong>(N&nbsp;=&nbsp;338)</strong></p></td><td><p><strong>Eylea 2Q8</strong></p><p><strong>(N&nbsp;=&nbsp;336)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Change in total lesion area from baseline [mm<sup>2</sup>]</strong></p></td></tr><tr><td style="vertical-align:top"><p>LS mean <sup>A</sup></p></td><td><p>12</p></td><td colspan="2"><p>-0.55</p></td><td><p>‑0.30</p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="3"><p>48</p></td><td><p>‑0.4 (2.9)</p></td><td><p>‑0.2 (3.1)</p></td><td><p>0.1 (3.6)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td><p>-0.46 (0.19)</p></td><td><p>-0.35 (0.20)</p></td><td><p>0.09 (0.22)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td><p>-0.55</p><p>(‑1.04, ‑0.06)</p></td><td><p>-0.44</p><p>(‑0.94, ‑0.06)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="3"><p>60</p></td><td><p>‑0.5 (2.8)</p></td><td><p>‑0.4 (3.2)</p></td><td><p>‑0.3 (3.2)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td><p>-0.48 (0.20)</p></td><td><p>-0.54 (0.21)</p></td><td><p>‑0.24 (0.20)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td><p>-0.24</p><p>(‑0.72, 0.24)</p></td><td><p>-0.29</p><p>(‑0.79, 0.20)</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><sup>A</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LS mean, CI and p‑value based on an MMRM with baseline best corrected visual acuity (BCVA) measurement as covariate, treatment group as factor, visit and stratification variables used for randomisation (geographical region, categorical baseline BCVA) as fixed factors as well as terms for the interaction between baseline BCVA and visit and for the interaction between treatment and visit.</p><p><sup>B</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute difference is Eylea 8Q12‑ or 8Q16‑groups minus 2Q8‑groups, respectively.</p><p>CI:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidence interval</p><p>LS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Least square</p><p>SD:&nbsp;&nbsp;&nbsp;&nbsp; Standard deviation</p><p>SE: &nbsp;&nbsp;&nbsp;&nbsp; Standard error</p><p>&nbsp;</p><p><strong>Figure&nbsp;1: LS mean change in central retinal thickness (CRT) from baseline through week&nbsp;60 (full analysis set) in the PULSAR study</strong><!--[if gte vml 1]><v:group
 id="Gruppieren_x0020_34" o:spid="_x0000_s1035" style='position:absolute;
 margin-left:2.55pt;margin-top:26.4pt;width:275.2pt;height:189.6pt;z-index:251658245;
 mso-position-horizontal-relative:text;mso-position-vertical-relative:text;
 mso-width-relative:margin;mso-height-relative:margin' coordsize="34959,24095"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textfeld_x0020_13" o:spid="_x0000_s1036" type="#_x0000_t202"
  style='position:absolute;left:22863;top:21618;width:12096;height:2477;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>weeks<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Textfeld_x0020_30" o:spid="_x0000_s1037" type="#_x0000_t202"
  style='position:absolute;left:-8855;top:8855;width:22948;height:5238;
  rotation:-90;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>LS mean change in CRT (microns)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:anchorlock/>
</v:group><![endif]--><img width="370" height="255" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p><strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Grafik_x0020_45" o:spid="_x0000_i1028" type="#_x0000_t75"
 style='width:453.5pt;height:207.5pt;visibility:visible;mso-wrap-style:square'
 o:bordertopcolor="yellow pure" o:borderleftcolor="yellow pure"
 o:borderbottomcolor="yellow pure" o:borderrightcolor="yellow pure">
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg"
  o:title=""/>
 <w:bordertop type="single" width="6"/>
 <w:borderleft type="single" width="6"/>
 <w:borderbottom type="single" width="6"/>
 <w:borderright type="single" width="6"/>
</v:shape><![endif]--><img width="606" height="278" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg" /></strong></p><p><strong>&nbsp;</strong></p><p><em><u>DME</u></em></p><p><em>&nbsp;</em></p><p>Diabetic macular oedema is characterised by increased vasopermeability and damage to the retinal capillaries which may result in loss of visual acuity.</p><p><em>&nbsp;</em></p><p>The pharmacodynamic effects of aflibercept 114.3&nbsp;mg/ml administered every 12 (8Q12) and every 16 (8Q16) weeks are described in comparison with aflibercept 40&nbsp;mg/ml administered every 8&nbsp;weeks (2Q8) for the DME indication. These effects are shown as the change in the leakage area from baseline to weeks&nbsp;48 and 60.</p><p>&nbsp;</p><p><strong>Table&nbsp;3</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-GB style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span><span style='mso-spacerun:yes'>  </span></span></b><![endif]--><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--><strong>: Pharmacodynamic parameter (full analysis set) in the PHOTON study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td><p><strong>Efficacy Outcomes</strong></p></td><td><p><strong>Week</strong></p></td><td><p><strong>Eylea 8Q12</strong></p><p><strong>(N&nbsp;=&nbsp;328)</strong></p></td><td><p><strong>Eylea 8Q16</strong></p><p><strong>(N&nbsp;=&nbsp;163)</strong></p></td><td><p><strong>Eylea 2Q8</strong></p><p><strong>(N&nbsp;=&nbsp;167)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Change in leakage area from baseline [mm<sup>2</sup>] </strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td><p>48</p></td><td><p>‑13.9 (13.91)</p></td><td><p>‑9.4 (11.50)</p></td><td><p>‑9.2 (12.11)</p></td></tr><tr><td><p>60</p></td><td><p>‑13.9 (13.54)</p></td><td><p>‑12.0 (13.26)</p></td><td><p>‑14.4 (12.89)</p></td></tr></tbody></table><p>SD:&nbsp;&nbsp;&nbsp;&nbsp; Standard deviation</p><p>&nbsp;</p><p><strong>Figure&nbsp;2: LS mean change in central retinal thickness (CRT) from baseline through week&nbsp;60 (full analysis set) in the PHOTON study</strong><!--[if gte vml 1]><v:group
 id="Gruppieren_x0020_33" o:spid="_x0000_s1032" style='position:absolute;
 margin-left:2.55pt;margin-top:31.95pt;width:274.35pt;height:185.95pt;
 z-index:251658244;mso-position-horizontal-relative:text;
 mso-position-vertical-relative:text;mso-width-relative:margin;
 mso-height-relative:margin' coordsize="34864,23618" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAf+2pEgIEAACrDgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsV9tuGzcQfS/QfyD41D442ptWF2Qd
yG5tBDAcQ3KQZ5riSotwyS1J3fL1PeTu2rJap+kNeTEESCRn9nDmzPBQ+/bdvpZkK4yttCpo/Cai
RCiul5VaFfTj/dXZmBLrmFoyqZUo6EFY+u78xx/esunKsGZdcQIEZaesoGvnmulgYPla1My+0Y1Q
sJXa1MxhalaDpWE7INdykERRPqhZpej5E9QvzDGyMdU/gJKafxbLS6a2zAJS8unxShej5P8emU3V
9to0i+bO+Mj57fbOkGpZUDCnWA2K6KAzdG6YDk6eWj0B7EtTe39dlmRf0EmajOMhJYeCJukkGo2G
LZzYO8JhT7NxlmRw4MEjj4d558HXH74Owde//gUIwmzDweAoxDD0Mb6QeZr2qV+bTdNUwghFsPid
eUBBwFHUhXGcfJ7laOuewfE48T4vJG+bNvM/FjxO+rTvUZ1SyCXBUp+09yduf6FRtLjDV9sexXbt
c1L9JBnlowno9MWN4yxJO8C+/HESTXL0RBt8NsqHIb/H2Nm0MdZdC10TPyioEdyFI8a2N9a1afYu
ITF9VUkZgpaK7Aqap4B8ZgG4VIGfPmq3XwRWfHrLg3d+wC/yNRpbgnfb8KsK+98w6+6YgTZgESrj
PuCrlBr7cFk1lKy1+XK65v1wTmGhZAeNKaj9bcOMoES+VxZHJM4ywLkwyYajBBNzbHk4tqhNfaml
r4GPKgy9v5P9sDS6/qTNcuZ3hYkpjr0L6vrhpcMMBggZF7NZGHNdN8zdqEUDSYkDX57V+/0nZpqO
eoei3erFmjXizyrQ+rZMzzZOl1VXnpZLb5DWLdxBilCewLhvqpqZmxAEBvM2ZLmCeHNnwj7SR+Uf
R753zpIt8+mnUd8px/YLUZ569m54+sk6K91X/DqrYw/oMe+HEWk0apXmUeTVioUIZXcOekd0VncO
jH/KIDnJ/MUj1Nn1BQr2BYFHCNxbRVmil9smBjXMVYq4QyNKxiG6M1MxSUnDlLaYRkl0EeVRht/+
k8FaOb6+YnUlcb5SLPA1M1aEugeOBTuCvK9qYcmt2JG5rpl6Bp4API2G2GCIDdLoFDz2+vIMHLki
v0DO+U6Iz9YLDsjy6yE9tfQnZX7MwcdFxwFI+AYO/tuAwfj/yoZ4TDiQgPb2hDwqysaKRTNHxVvN
aiUHHq0ev6zKCbqtvYcfVRlLobq4q73+fpsqt1oW5/ij0ndgd0WfjcfDYTQKIt0N2+bpbtckmWTj
CQTDXzDDJB23dzhi79W+F+BXjW7V+1WjXzU66PSpjH5Hjb5ZkFow5VVcrQTBZXM5vyc/1RU3Wtmf
X9W7v67+tnpDCLs3isHJa1qA6l4r/bvg8fz8dwAAAP//AwBQSwMEFAAGAAgAAAAhAJJ9h+AdBwAA
SSAAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZS28bNxC+F+h/WOy9sWS9YiNyYMly
3MQvREqKHCmJ2mXMXS5Iyo5uRXLqpUCBtOihAXrroSgaoAEa9NIfY8BBm/6IDrkvUqLiB1wgKGwB
xu7sN8PhzOzM7PDO3WcR9Y4xF4TFbb96q+J7OB6xMYmDtv9osP3Zbd8TEsVjRFmM2/4MC//uxqef
3EHrI0qSIUN8PAhxhD0QFIt11PZDKZP1lRUxAjISt1iCY3g2YTxCEm55sDLm6AQWiOjKaqXSXIkQ
if0NkCiVoB6Ff7EUijCivK/EYC9GEax+MJmQEdbY8VFVIcRMdCn3jhFt+yBzzE4G+Jn0PYqEhAdt
v6L//JWNOytoPWOicgmvwbet/zK+jGF8tKrX5MGwWLReb9Sbm4V8DaByEddr9Zq9ZiFPA9BoBDtN
dbFltla79QxrgNJLh+yt1latauEN+bUFnTcb6mfhNSiVX1/Ab293wYoWXoNSfGMB3+isdbZs+RqU
4psL+FZlc6vesuRrUEhJfLSArjSatW6+2wIyYXTHCV9r1Ldbq5nwEgXRUESXWmLCYrks1iL0lPFt
ACggRZLEnpwleIJGEJNdRMmQE2+XBCEEXoJiJoBcWa1sV2rwX/3q+kp7FK1jZHArvUATsUBS+nhi
xEki2/59kOobkLO3b0+fvzl9/vvpixenz3/N1taiLL4dFAcm3/ufvvnn1Zfe37/9+P7lt+nS83hh
4t/98tW7P/78kHjYcWmKs+9ev3vz+uz7r//6+aVD+iZHQxM+IBEW3j4+8R6yCDbo0B8P+eU4BiEi
JsdmHAgUI7WKQ35PhhZ6f4YocuA62LbjYw6pxgW8N31qKdwP+VQSh8QHYWQB9xijHcadVnig1jLM
PJjGgXtxPjVxDxE6dq3dRbHl5d40gRxLXCK7IbbUPKQolijAMZaeesaOMHbs7gkhll33yIgzwSbS
e0K8DiJOkwzI0IqmkmmHROCXmUtB8Ldlm73HXodR16638LGNhHcDUYfyA0wtM95DU4kil8gBiqhp
8F0kQ5eS/RkfmbiekODpAFPm9cZYCBfPAYf9Gk5/AGnG7fY9OotsJJfkyCVzFzFmIrfYUTdEUeLC
9kkcmtjPxRGEKPIOmXTB95j9hqh78AOKl7r7McGWu8/PBo8gw5oqlQGinky5w5f3MLPitz+jE4Rd
qWaTR1aK3eTEGR2daWCF9i7GFJ2gMcbeo88dGnRYYtm8VPp+CFllB7sC6z6yY1Xdx1hgTzc3i3ly
lwgrZPs4YEv02ZvNJZ4ZiiPEl0neB6+bNu9BqYtcAXBAR0cmcJ9Avwfx4jTKgQAZRnAvlXoYIquA
qXvhjtcZt/x3kXcM3sunlhoXeC+BB1+aBxK7yfNB2wwQtRYoA2aAoMtwpVtgsdxfsqjiqtmmTr6J
/dKWboDuyGp6IhKf2wHN9T6N/673gQ7j7IdXjpftevodt2ArWV2y01mWTHbm+ptluPmupsv4mHz8
Tc0WmsaHGOrIYsa66Wluehr/f9/TLHufbzqZZf3GTSfjQ4dx08lkw5Xr6WTK5gX6GjXwSAc9euwT
LZ36TAilfTmjeFfowY+A75nxNhAVn55u4mIKmIRwqcocLGDhAo40j8eZ/ILIsB+iBKZDVV8JCUQm
OhBewgQMjTTZKVvh6TTaY+N02FmtqsFmWlkFkiW90ijoMKiSKbrZKgd4hXitbaAHrbkCivcyShiL
2UrUHEq0cqIykh7rgtEcSuidXYsWaw4tbivxuasWtADVCq/AB7cHn+ltv1EHFmCCeRw052Plp9TV
uXe1M6/T08uMaUUANNh5BJSeXlO6Lt2e2l0aahfwtKWEEW62EtoyusETIXwGZ9GpqBdR47K+Xitd
aqmnTKHXg9Aq1Wjd/pAWV/U18M3nBhqbmYLG3knbb9YaEDIjlLT9CQyN4TJKIHaE+uZCNIDjlpHk
6Qt/lcyScCG3kAhTg+ukk2aDiEjMPUqitq+2X7iBxjqHaN2qq5AQPlrl1iCtfGzKgdNtJ+PJBI+k
6XaDoiyd3kKGT3OF86lmvzpYcbIpuLsfjk+8IZ3yhwhCrNGqKgOOiYCzg2pqzTGBw7AikZXxN1eY
srRrnkbpGErpiCYhyiqKmcxTuE7lhTr6rrCBcZftGQxqmCQrhMNAFVjTqFY1LapGqsPSqns+k7Kc
kTTLmmllFVU13VnMWiEvA3O2vFqRN7TKTQw5zazwaeqeT7lrea6b6xOKKgEGL+znqLoXKAiGauVi
lmpK48U0rHJ2RrVrR77Bc1S7SJEwsn4zFztnt6JGOJcD4pUqP/DNRy2QJnlfqS3tOtjeQ4k3DKpt
Hw6XYTj4DK7geNoH2qqirSoaXMGZM5SL9KC47WcXOQWep5QCU8sptRxTzyn1nNLIKY2c0swpTd/T
J6pwiq8OU30vPzCFGpYdsGa9hX36v/EvAAAA//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAA
KgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74Lv
EPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsv
uyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZV
dWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAA
AP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRl
bnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYB
AABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQB/7akSAgQAAKsOAAAfAAAAAAAAAAAAAAAAACAC
AABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAJJ9h+AdBwAA
SSAAABoAAAAAAAAAAAAAAAAAXwYAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAG
AAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAAtA0AAGNsaXBib2FyZC9kcmF3aW5ncy9f
cmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAAC3DgAAAAA=
">
 <v:shape id="Textfeld_x0020_12" o:spid="_x0000_s1033" type="#_x0000_t202"
  style='position:absolute;left:22767;top:21142;width:12097;height:2476;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>weeks<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Textfeld_x0020_25" o:spid="_x0000_s1034" type="#_x0000_t202"
  style='position:absolute;left:-8855;top:8855;width:22948;height:5238;
  rotation:-90;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>LS mean change in CRT (microns)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:anchorlock/>
</v:group><![endif]--><img width="369" height="251" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p><!--[if gte vml 1]><v:shape
 id="Grafik_x0020_47" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:453.5pt;
 height:209pt;visibility:visible;mso-wrap-style:square' o:bordertopcolor="yellow pure"
 o:borderleftcolor="yellow pure" o:borderbottomcolor="yellow pure"
 o:borderrightcolor="yellow pure">
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
  o:title=""/>
 <w:bordertop type="single" width="6"/>
 <w:borderleft type="single" width="6"/>
 <w:borderbottom type="single" width="6"/>
 <w:borderright type="single" width="6"/>
</v:shape><![endif]--><img width="606" height="280" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p>After dosing with Eylea&nbsp;114.3&nbsp;mg/ml for up to 48&nbsp;weeks treatment‑emergent antibodies to Eylea&nbsp;114.3&nbsp;mg/ml were detected in 1.2% to 3.8% of patients treated for DME and nAMD. No evidence of anti‑drug antibodies impact on pharmacokinetics, efficacy or safety was observed.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>nAMD</u></em></p><p><em>&nbsp;</em></p><p><em>Study objectives</em></p><p>The safety and efficacy of Eylea&nbsp;114.3&nbsp;mg/ml were assessed in a randomised, multi‑centre, double‑masked, active‑controlled study (PULSAR) in patients with treatment na&iuml;ve nAMD.</p><p>&nbsp;</p><p>The primary objective was to determine if treatment with Eylea&nbsp;114.3&nbsp;mg/ml at intervals of&nbsp;12 (8Q12) or 16&nbsp;weeks (8Q16) provides non‑inferior best corrected visual acuity (BCVA) change compared to Eylea&nbsp;40&nbsp;mg/ml every 8&nbsp;weeks in patients with nAMD.</p><p>The secondary objectives were to determine the effect of Eylea&nbsp;114.3&nbsp;mg/ml versus Eylea&nbsp;40&nbsp;mg/ml on anatomic and other visual measures of response, and to evaluate the safety, immunogenicity, and pharmacokinetics of aflibercept.</p><p>&nbsp;</p><p>The primary efficacy endpoint was the change from baseline in BCVA measured by the early treatment diabetic retinopathy study (ETDRS) letter score at week&nbsp;48.</p><p>The key secondary endpoints were the change in BCVA from baseline at week&nbsp;60 and the proportion of patients with no intraretinal fluid (IRF) and no subretinal fluid (SRF) in central subfield at week&nbsp;16.</p><p>Further secondary endpoints were the proportion of patients gaining at least 15&nbsp;letters in BCVA from baseline at week&nbsp;48, the proportion of patients achieving an ETDRS letter score of at least&nbsp;69 (approximate 20/40 Snellen equivalent) at week&nbsp;48, and the change from baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) total score at week&nbsp;48, among others.</p><p>&nbsp;</p><p>In the PULSAR study a total of 1&nbsp;009&nbsp;patients were treated. The patients were assigned in a 1:1:1 ratio to&nbsp;1 of&nbsp;3 parallel treatment groups:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;114.3&nbsp;mg/ml administered every 12&nbsp;weeks (8Q12)</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;114.3&nbsp;mg/ml administered every 16&nbsp;weeks (8Q16)</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;40&nbsp;mg/ml administered every 8&nbsp;weeks (2Q8)</p><p>&nbsp;</p><p>All patients received 3&nbsp;initial injections of the assigned dose at 4‑week intervals.</p><p>Per study protocol the interval of the 8Q12‑ and 8Q16‑groups was to be shortened if both of the following criteria were met:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;5&nbsp;letters loss in BCVA from week&nbsp;12, and</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;25&nbsp;microns increase in CRT from week&nbsp;12 or new foveal haemorrhage or new foveal neovascularisation.</p><p>&nbsp;</p><p>Regardless of whether patient intervals were maintained or shortened in year&nbsp;1, per study protocol all patients in the 8Q12‑ and 8Q16‑groups were eligible for interval extension (by 4&nbsp;weeks increments), beginning at week&nbsp;52, if the following criteria were met:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;5&nbsp;letters loss in BCVA from week&nbsp;12, and</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; no fluid in the central subfield on optical coherence tomography (OCT), and</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; no new onset of foveal haemorrhage or foveal neovascularisation.</p><p>&nbsp;</p><p>For patients who did not meet the criteria for shortening or extension of the interval, the dosing interval was maintained. The minimum interval between injections was 8&nbsp;weeks in all groups.</p><p>Patients with bilateral disease were eligible to receive Eylea&nbsp;40&nbsp;mg/ml treatment or another anti‑VEGF medicinal product in their fellow eye.</p><p>&nbsp;</p><p><em>Patient characteristics at baseline</em></p><p>Patient ages ranged from 50&nbsp;to&nbsp;96&nbsp;years with a mean of 74.5&nbsp;years.</p><p>Approximately 92% (309/335) and 87% (295/338) of the patients randomised to the 8Q12‑ and 8Q16‑groups, respectively, were 65&nbsp;years of age or older and approximately 51% (172/335) and 51% (171/338) were 75&nbsp;years of age or older.</p><p>&nbsp;</p><p><em>Results</em></p><p>Patients in the 8Q12‑, 8Q16‑ and 2Q8‑groups who completed week&nbsp;48 received a median (mean) of 6.0 (6.1), 5.0 (5.2) and 7.0 (6.9) injections, respectively.</p><p>At week&nbsp;48, in the 8Q12‑group, 79.4% of patients maintained Q12 intervals while in the 8Q16‑group 76.6% of patients maintained Q16 intervals.</p><p>Patients in the 8Q12‑, 8Q16‑ and 2Q8‑groups who completed week&nbsp;60 received a median (mean) of 7.0 (7.1), 6.0 (6.2) and 9.0 (8.8) injections, respectively.</p><p>At week&nbsp;60, 43.1% of patients in the 8Q12‑group were extended to a dosing interval of 16&nbsp;weeks, and 38.5% of patients in the 8Q16‑group were extended to a dosing interval of 20&nbsp;weeks.</p><p>&nbsp;</p><p>Treatment with 8Q12 and 8Q16 was shown to be non‑inferior and clinically equivalent to treatment with 2Q8 in terms of the primary efficacy endpoint &lsquo;mean change in BCVA at week&nbsp;48&rsquo; and the key secondary efficacy endpoint &lsquo;mean change in BCVA at week&nbsp;60&rsquo;.</p><p>&nbsp;</p><p>Furthermore, treatment with Eylea (pooled 8Q12‑ and 8Q16‑groups) was shown to be superior to treatment with 2Q8 in terms of the key secondary efficacy endpoint &lsquo;proportion of patients with no intraretinal fluid (IRF) and no subretinal fluid (SRF) in the central subfield at week&nbsp;16&rsquo; (see table&nbsp;4).</p><p>&nbsp;</p><p><strong>Table&nbsp;4: Efficacy outcomes from the PULSAR study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td><p><strong>Efficacy outcomes</strong></p></td><td><p><strong>Week</strong></p></td><td><p><strong>Eylea 8Q12</strong></p><p><strong>(N&nbsp;=&nbsp;335)</strong></p></td><td><p><strong>Eylea 8Q16</strong></p><p><strong>(N&nbsp;=&nbsp;338)</strong></p></td><td><p><strong>Eylea 2Q8</strong></p><p><strong>(N&nbsp;=&nbsp;336)</strong></p></td></tr><tr><td colspan="5"><p><strong>Change in BCVA from baseline as measured by ETDRS letter score <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="4"><p>48</p></td><td style="vertical-align:top"><p>6.7 (12.6)</p></td><td style="vertical-align:top"><p>6.2 (11.7)</p></td><td style="vertical-align:top"><p>7.6 (12.2)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td style="vertical-align:top"><p>6.06 (0.77)</p></td><td style="vertical-align:top"><p>5.89 (0.72)</p></td><td style="vertical-align:top"><p>7.03 (0.74)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td style="vertical-align:top"><p>-0.97</p><p>(‑2.87, 0.92)</p></td><td style="vertical-align:top"><p>-1.14</p><p>(‑2.97, 0.69)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value (one‑sided non‑inferiority test at a margin of 4&nbsp;letters) <sup>A,B</sup></p></td><td><p>0.0009</p></td><td><p>0.0011</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="4"><p>60</p></td><td style="vertical-align:top"><p>6.6 (13.6)</p></td><td style="vertical-align:top"><p>6.6 (11.7)</p></td><td style="vertical-align:top"><p>7.8 (12.6)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td style="vertical-align:top"><p>6.37 (0.74)</p></td><td style="vertical-align:top"><p>6.31 (0.66)</p></td><td style="vertical-align:top"><p>7.23 (0.68)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td style="vertical-align:top"><p>-0.86</p><p>(‑2.57, 0.84)</p></td><td style="vertical-align:top"><p>-0.92</p><p>(‑2.51, 0.66)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value (one‑sided non‑inferiority test at a margin of 4&nbsp;letters) <sup>A,B</sup></p></td><td><p>0.0002</p></td><td><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Patients with no IRF and no SRF in the central subfield <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="3"><p>16</p></td><td colspan="2" style="vertical-align:top"><p>63.3%</p></td><td style="vertical-align:top"><p>51.6%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td colspan="2"><p>11.7% (5.3%, 18.2%)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value (one‑sided superiority test) <sup>B, C</sup></p></td><td colspan="2"><p>0.0002</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>48</p></td><td style="vertical-align:top"><p>71.1%</p></td><td style="vertical-align:top"><p>66.8%</p></td><td style="vertical-align:top"><p>59.4%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>11.7%</p><p>(4.5%, 18.9%)</p></td><td style="vertical-align:top"><p>7.5%</p><p>(0.1%, 14.8%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>60</p></td><td style="vertical-align:top"><p>74.6%</p></td><td style="vertical-align:top"><p>72.2%</p></td><td style="vertical-align:top"><p>74.6%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>0.0%</p><p>(‑6.6%, 6.7%)</p></td><td style="vertical-align:top"><p>‑2.2%</p><p>(‑8.9%, 4.4%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Patients achieving an ETDRS letter score of at least&nbsp;69 (approximate 20/40&nbsp;Snellen equivalent) <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>48</p></td><td style="vertical-align:top"><p>56.9%</p></td><td style="vertical-align:top"><p>54.3%</p></td><td style="vertical-align:top"><p>57.9%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>‑0.2%</p><p>(‑6.6%, 6.2%)</p></td><td style="vertical-align:top"><p>‑2.2%</p><p>(‑8.4%, 4.0%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>60</p></td><td style="vertical-align:top"><p>56.3%</p></td><td style="vertical-align:top"><p>54.6%</p></td><td style="vertical-align:top"><p>58.2%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>‑1.1%</p><p>(‑7.5%, 5.3%)</p></td><td style="vertical-align:top"><p>‑2.3%</p><p>(‑8.7%, 4.1%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Patients who gained at least 15&nbsp;letters in BCVA from baseline <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>48</p></td><td style="vertical-align:top"><p>20.7%</p></td><td style="vertical-align:top"><p>21.7%</p></td><td style="vertical-align:top"><p>22.1%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>‑1.7%</p><p>(‑7.8%, 4.3%)</p></td><td style="vertical-align:top"><p>‑0.9%</p><p>(‑7.0%, 5.1%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>60</p></td><td style="vertical-align:top"><p>23.7%</p></td><td style="vertical-align:top"><p>23.1%</p></td><td style="vertical-align:top"><p>23.3%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>0.1%</p><p>(‑6.2%, 6.3%)</p></td><td style="vertical-align:top"><p>‑0.7%</p><p>(‑6.9%, 5.5%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>A</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LS mean, CI and p‑value based on an MMRM with baseline best corrected visual acuity (BCVA) measurement as covariate, treatment group as factor, visit and stratification variables used for randomisation (geographical region, categorical baseline BCVA) as fixed factors as well as terms for the interaction between baseline BCVA and visit and for the interaction between treatment and visit.</p><p><sup>B</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute difference is Eylea 8Q12‑ or 8Q16‑groups minus 2Q8‑groups, respectively.</p><p><sup>C</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mantel‑Haenszel weighted treatment difference with stratification variables used for randomization (geographical region, categorical baseline BCVA) and CI calculated using normal approximation.</p><p><sup>D</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Full analysis set</p><p>CI:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidence interval</p><p>LOCF: Last observation carried forward</p><p>LS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Least square</p><p>SD:&nbsp;&nbsp;&nbsp;&nbsp; Standard deviation</p><p>SE: &nbsp;&nbsp;&nbsp;&nbsp; Standard error</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="Gruppieren_x0020_32" o:spid="_x0000_s1029"
 style='position:absolute;margin-left:2.45pt;margin-top:29.45pt;width:276.65pt;
 height:173.15pt;z-index:251658243;mso-width-relative:margin;
 mso-height-relative:margin' coordsize="35150,22020" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Textfeld_x0020_11" o:spid="_x0000_s1030" type="#_x0000_t202"
  style='position:absolute;left:23053;top:19544;width:12097;height:2476;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>weeks<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Textfeld_x0020_17" o:spid="_x0000_s1031" type="#_x0000_t202"
  style='position:absolute;left:-7760;top:7760;width:20758;height:5238;
  rotation:-90;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>LS mean change visual acuity<o:p></o:p></span></p>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>(letters)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:anchorlock/>
</v:group><![endif]--><img width="371" height="233" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><strong>Figure&nbsp;3: LS mean change in BCVA as measured by ETDRS letter score from baseline through week&nbsp;60 (full analysis set) in the PULSAR study</strong></p><p><strong><!--[if gte vml 1]><v:shape id="Grafik_x0020_49"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:453.5pt;height:198.5pt;
 visibility:visible;mso-wrap-style:square' o:bordertopcolor="yellow pure"
 o:borderleftcolor="yellow pure" o:borderbottomcolor="yellow pure"
 o:borderrightcolor="yellow pure">
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image008.jpg"
  o:title=""/>
 <w:bordertop type="single" width="6"/>
 <w:borderleft type="single" width="6"/>
 <w:borderbottom type="single" width="6"/>
 <w:borderright type="single" width="6"/>
</v:shape><![endif]--><img width="606" height="266" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image009.jpg" /></strong></p><p>&nbsp;</p><p>Aflibercept at all doses (8Q12, 8Q16, 2Q8) demonstrated meaningful increase from baseline in the pre‑specified secondary efficacy endpoint national eye institute visual function questionnaire (NEI VFQ‑25).</p><p>No clinically meaningful differences were found between the 8Q12‑, 8Q16‑ and 2Q8‑groups in changes of NEI VFQ‑25 total score at week&nbsp;48 from baseline.</p><p>&nbsp;</p><p>Efficacy results in evaluable subgroups for age, gender, geographic region, ethnicity, race, baseline BCVA, and lesion type were consistent with the results in the overall population.</p><p>Efficacy was generally maintained through week&nbsp;60.</p><p>&nbsp;</p><p><em><u>DME</u></em></p><p>&nbsp;</p><p><em>Study objectives</em></p><p>The safety and efficacy of Eylea&nbsp;114.3&nbsp;mg/ml were assessed in a randomised, multi‑centre, double‑masked, active‑controlled study (PHOTON) in patients with DME.</p><p>&nbsp;</p><p>The primary objective was to determine if treatment with Eylea&nbsp;114.3&nbsp;mg/ml at intervals of&nbsp;12 (8Q12) or 16&nbsp;weeks (8Q16) provides non‑inferior BCVA change compared to Eylea&nbsp;40&nbsp;mg/ml every 8&nbsp;weeks.</p><p>The secondary objectives were to determine the effect of Eylea&nbsp;114.3&nbsp;mg/ml versus Eylea&nbsp;40&nbsp;mg/ml on anatomic and other visual measures of response, and to evaluate the safety, immunogenicity, and pharmacokinetics of aflibercept.</p><p><em>&nbsp;</em></p><p>The primary efficacy endpoint was the change from baseline in BCVA measured by the early treatment diabetic retinopathy study (ETDRS) letter score at week&nbsp;48.</p><p>One key secondary endpoint was the change in BCVA from baseline at week&nbsp;60.</p><p>Further secondary endpoints were the proportion of patients gaining at least 15&nbsp;letters in BCVA from baseline at week&nbsp;48, the proportion of patients achieving an ETDRS letter score of at least&nbsp;69 (approximate 20/40 Snellen equivalent) at week&nbsp;48, and the change from baseline in National Eye Institute Visual Functioning Questionnaire‑25 (NEI‑VFQ‑25) total score at week&nbsp;48, among others.</p><p>&nbsp;</p><p>In the PHOTON study a total of 658&nbsp;patients were treated. The patients were assigned in a 2:1:1 ratio to&nbsp;1 of&nbsp;3 parallel treatment groups:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;114.3&nbsp;mg/ml administered every 12&nbsp;weeks (8Q12)</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;114.3&nbsp;mg/ml administered every 16&nbsp;weeks (8Q16)</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;40&nbsp;mg/ml administered every 8&nbsp;weeks (2Q8)</p><p>&nbsp;</p><p>All patients in the 8Q12‑ and 8Q16‑groups received 3&nbsp;initial injections and all patients in the 2Q8‑group received 5&nbsp;initial injections at 4‑week intervals.</p><p>Per study protocol the interval of the 8Q12‑ and 8Q16‑groups was to be shortened if both of the following criteria were met:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;10&nbsp;letter loss in BCVA from week&nbsp;12 in association with persistent or worsening DME, and</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;50&nbsp;microns increase in CRT from week&nbsp;12.</p><p>&nbsp;</p><p>Regardless of whether patient intervals were maintained or shortened in year&nbsp;1, per study protocol all patients in the 8Q12‑ and 8Q16‑groups were eligible for interval extension (by 4&nbsp;weeks increments), beginning at week&nbsp;52, if the following criteria were met:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;5&nbsp;letter loss in BCVA from week&nbsp;12, and</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CRT &lt;300&nbsp;microns on SD‑OCT (or &lt;320&nbsp;microns if measured including RPE).</p><p>&nbsp;</p><p>For patients who did not meet the criteria for shortening or extension of the interval, the dosing interval was maintained. The minimum interval between injections was 8&nbsp;weeks in all groups.</p><p>Patients with bilateral disease were eligible to receive Eylea&nbsp;40&nbsp;mg/ml treatment in their fellow eye.</p><p><em>&nbsp;</em></p><p><em>Patient characteristics at baseline</em></p><p>Patient ages ranged from 24&nbsp;to&nbsp;90&nbsp;years with a mean of 62.3&nbsp;years.</p><p>Approximately 44% (143/328) and 44% (71/163) of the patients randomised to the 8Q12‑ and 8Q16‑groups, respectively, were 65&nbsp;years of age or older and approximately 11% (36/328) and 14% (14/163) were 75&nbsp;years of age or older.</p><p>The proportion of patients who were treated previously for DME was balanced between the treatment groups (43.6% in 8Q12‑, 43.6% in 8Q16‑, 44.3% in 2Q8‑group).</p><p>&nbsp;</p><p><em>Results</em></p><p>Patients in the 8Q12‑, 8Q16‑ and 2Q8‑groups who completed week&nbsp;48 received a median (mean) of 6.0 (6.0), 5.0 (5.0) and 8.0 (7.9) injections, respectively.</p><p>At week&nbsp;48, in the 8Q12‑group, 91.0% of patients maintained Q12 intervals while in the 8Q16‑group 89.1% of patients maintained Q16 intervals.</p><p>Patients in the 8Q12‑, 8Q16‑ and 2Q8‑groups who completed week&nbsp;60 received a median (mean) of 7.0 (7.0), 6.0 (6.0) and 10.0 (9.8) injections, respectively. At week&nbsp;60, 42.6% of patients in the 8Q12‑group were extended to a dosing interval of 16&nbsp;weeks, and 34.2% of patients in the 8Q16‑group were extended to a dosing interval of 20&nbsp;weeks.</p><p>&nbsp;</p><p>Treatment with Eylea (both 8Q12‑ and 8Q16‑groups) was shown to be non‑inferior and clinically equivalent to treatment with 2Q8 in terms of the primary efficacy endpoint &lsquo;mean change in BCVA at week&nbsp;48&rsquo; and the key secondary efficacy endpoint &lsquo;mean change in BCVA at week&nbsp;60&rsquo;.</p><p>&nbsp;</p><p><strong>Table&nbsp;5: Efficacy outcomes from the PHOTON study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td><p><strong>Efficacy outcomes</strong></p></td><td><p><strong>Week</strong></p></td><td><p><strong>Eylea 8Q12</strong></p><p><strong>(N&nbsp;=&nbsp;328)</strong></p></td><td><p><strong>Eylea 8Q16</strong></p><p><strong>(N&nbsp;=&nbsp;163)</strong></p></td><td><p><strong>Eylea 2Q8</strong></p><p><strong>(N&nbsp;=&nbsp;167)</strong></p></td></tr><tr><td colspan="5"><p><strong>Change in BCVA from baseline as measured by ETDRS letter score <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="4"><p>48</p></td><td><p>8.77 (8.95)</p></td><td><p>7.86 (8.38)</p></td><td><p>9.21 (8.99)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td><p>8.10 (0.61)</p></td><td><p>7.23 (0.71)</p></td><td><p>8.67 (0.73)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td><p>‑0.57</p><p>(‑2.26, 1.13)</p></td><td><p>‑1.44</p><p>(‑3.27, 0.39)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value (one‑sided non‑inferiority test at a margin of 4&nbsp;letters) <sup>A,B</sup></p></td><td><p>&lt;0.0001</p></td><td><p>0.0031</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="4"><p>60</p></td><td><p>9.05 (9.27)</p></td><td><p>7.96 (9.14)</p></td><td><p>9.62 (9.58)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td><p>8.52 (0.63)</p></td><td><p>7.64 (0.75)</p></td><td><p>9.40 (0.77)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td><p>‑0.88</p><p>(‑2.67, 0.91)</p></td><td><p>‑1.76</p><p>(‑3.71, 0.19)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value (one‑sided non‑inferiority test at a margin of 4&nbsp;letters) <sup>A,B</sup></p></td><td><p>0.0003</p></td><td><p>0.0122</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Patients achieving an ETDRS letter score of at least&nbsp;69 (approximate 20/40 Snellen equivalent) <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>48</p></td><td style="vertical-align:top"><p>65.3%</p></td><td style="vertical-align:top"><p>62.6%</p></td><td style="vertical-align:top"><p>63.0%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>2.45%</p><p>(‑6.47%, 11.36%)</p></td><td style="vertical-align:top"><p>‑0.67%</p><p>(‑11.16%, 9.82%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>60</p></td><td style="vertical-align:top"><p>64.7%</p></td><td style="vertical-align:top"><p>62.0%</p></td><td style="vertical-align:top"><p>60.6%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>4.34%</p><p>(‑4.72%, 13.40%)</p></td><td style="vertical-align:top"><p>1.63%</p><p>(‑8.91%, 12.17%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Patients who gained at least 15&nbsp;letters in BCVA from baseline <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>48</p></td><td style="vertical-align:top"><p>18.7%</p></td><td style="vertical-align:top"><p>16.6%</p></td><td style="vertical-align:top"><p>23.0%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>‑4.64%</p><p>(‑12.30%, 3.02%)</p></td><td style="vertical-align:top"><p>‑7.14%</p><p>(‑15.45%, 1.17%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>60</p></td><td style="vertical-align:top"><p>21.5%</p></td><td style="vertical-align:top"><p>16.0%</p></td><td style="vertical-align:top"><p>26.1%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>‑5.01%</p><p>(‑13.04%, 3.02%)</p></td><td style="vertical-align:top"><p>‑10.78%</p><p>(‑19.27%, ‑2.29%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>A</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LS mean, CI and p‑value based on an MMRM with baseline best corrected visual acuity (BCVA) measurement as covariate, treatment group as factor, visit and stratification variables used for randomisation (geographical region, categorical baseline BCVA) as fixed factors as well as terms for the interaction between baseline BCVA and visit and for the interaction between treatment and visit.</p><p><sup>B</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute difference is Eylea 8Q12‑ or 8Q16‑groups minus 2Q8‑groups, respectively.</p><p><sup>C</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mantel‑Haenszel weighted treatment difference with stratification variables used for randomization (geographical region, categorical baseline BCVA) and CI calculated using normal approximation.</p><p><sup>D</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Full analysis set</p><p>CI:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidence interval</p><p>LOCF: Last observation carried forward</p><p>LS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Least square</p><p>SD:&nbsp;&nbsp;&nbsp;&nbsp; Standard deviation</p><p>SE: &nbsp;&nbsp;&nbsp;&nbsp; Standard error</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="Gruppieren_x0020_31" o:spid="_x0000_s1026"
 style='position:absolute;margin-left:1.1pt;margin-top:30.2pt;width:278.35pt;
 height:175.8pt;z-index:251658242;mso-width-relative:margin;
 mso-height-relative:margin' coordsize="35339,22375" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Textfeld_x0020_10" o:spid="_x0000_s1027" type="#_x0000_t202"
  style='position:absolute;left:23242;top:19898;width:12097;height:2477;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>weeks<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Textfeld_x0020_14" o:spid="_x0000_s1028" type="#_x0000_t202"
  style='position:absolute;left:-7762;top:7762;width:20761;height:5238;
  rotation:-90;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>LS mean change visual acuity<o:p></o:p></span></p>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>(letters)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:anchorlock/>
</v:group><![endif]--><img width="374" height="237" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" /><strong>Figure&nbsp;4: LS mean change in BCVA as measured by ETDRS letter score from baseline through week&nbsp;60 (full analysis set) in the PHOTON study</strong></p><p><!--[if gte vml 1]><v:shape
 id="Grafik_x0020_50" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:453.5pt;
 height:199pt;visibility:visible;mso-wrap-style:square' o:bordertopcolor="yellow pure"
 o:borderleftcolor="yellow pure" o:borderbottomcolor="yellow pure"
 o:borderrightcolor="yellow pure">
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image011.jpg"
  o:title=""/>
 <w:bordertop type="single" width="6"/>
 <w:borderleft type="single" width="6"/>
 <w:borderbottom type="single" width="6"/>
 <w:borderright type="single" width="6"/>
</v:shape><![endif]--><img width="606" height="267" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image012.jpg" /></p><p>&nbsp;</p><p>Eylea at all doses (8Q12, 8Q16, 2Q8) demonstrated meaningful increase from baseline in the pre‑specified secondary efficacy endpoint national eye institute visual function questionnaire (NEI VFQ‑25).</p><p>No clinically meaningful differences were found between the 8Q12‑, 8Q16‑ and 2Q8‑groups in changes of NEI VFQ‑25 total score at week&nbsp;48 from baseline.</p><p>&nbsp;</p><p>Efficacy results in evaluable subgroups for age, gender, geographic region, ethnicity, race, baseline BCVA and baseline CRT and prior DME treatment were consistent with the results in the overall population.</p><p>Efficacy was generally maintained through week&nbsp;60.</p><p>&nbsp;</p><p>Treatment effects in the sub‑group of previously treated patients were similar to those seen in patients who were treatment na&iuml;ve.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with aflibercept in all subsets of the paediatric population in nAMD and DME (see section&nbsp;4.2 for information on paediatric use).</p><p>Pharmacotherapeutic group: Ophthalmologicals / Antineovascularisation agents, ATC code:&nbsp;S01LA05</p><p>&nbsp;</p><p>Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptor&nbsp;1 and&nbsp;2 extracellular domains fused to the Fc portion of human IgG1.</p><p>&nbsp;</p><p>Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Vascular endothelial growth factor‑A (VEGF‑A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as potent mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR‑1 and VEGFR‑2, present on the surface of endothelial cells. PlGF binds only to VEGFR‑1, which is also present on the surface of leucocytes. Excessive activation of these receptors by VEGF‑A can result in pathological neovascularisation and excessive vascular permeability. PlGF can act independently to activate the VEGFR‑1 to promote an inflammatory response within the retina, and is known to increase in pathological states such as nAMD, diabetic retinopathy (DR), DME, and retinal vein occlusion (RVO).</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Aflibercept acts as a soluble decoy receptor that binds VEGF‑A and PlGF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors.</p><p>In animal studies, aflibercept can prevent pathological neovascularization and vascular leakage in a number of different models of ocular disease.</p><p>&nbsp;</p><p><em><u>nAMD</u></em></p><p><em>&nbsp;</em></p><p>nAMD is characterised by pathological choroidal neovascularisation (CNV). Leakage of blood and fluid from CNV may cause retinal oedema and/or sub‑/intra‑retinal haemorrhage, resulting in loss of visual acuity.</p><p>&nbsp;</p><p>The pharmacodynamic effects of aflibercept 114.3&nbsp;mg/ml administered every 12 (8Q12) and every 16 (8Q16) weeks are described in comparison with aflibercept 40 mg/ml administered every 8&nbsp;weeks (2Q8) for the nAMD indication. These effects are shown as the change in CNV size from baseline to week 12; change in total lesion area from baseline to weeks&nbsp;48 and 60; and change from baseline in central retinal thickness (CRT).</p><p>&nbsp;</p><p>In the pooled group of patients treated with 8Q12 or 8Q16, reductions in CNV size (LS mean, based on a mixed model for repeated measurements [MMRM]) at week&nbsp;12 were ‑1.63&nbsp;mm<sup>2</sup> compared to ‑1.17&nbsp;mm<sup>2</sup> for patients treated with 2Q8.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;2: Pharmacodynamic parameter (full analysis set) in the PULSAR study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td><p><strong>Efficacy outcomes</strong></p></td><td><p><strong>Week</strong></p></td><td><p><strong>Eylea 8Q12</strong></p><p><strong>(N&nbsp;=&nbsp;335)</strong></p></td><td><p><strong>Eylea 8Q16</strong></p><p><strong>(N&nbsp;=&nbsp;338)</strong></p></td><td><p><strong>Eylea 2Q8</strong></p><p><strong>(N&nbsp;=&nbsp;336)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Change in total lesion area from baseline [mm<sup>2</sup>]</strong></p></td></tr><tr><td style="vertical-align:top"><p>LS mean <sup>A</sup></p></td><td><p>12</p></td><td colspan="2"><p>-0.55</p></td><td><p>‑0.30</p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="3"><p>48</p></td><td><p>‑0.4 (2.9)</p></td><td><p>‑0.2 (3.1)</p></td><td><p>0.1 (3.6)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td><p>-0.46 (0.19)</p></td><td><p>-0.35 (0.20)</p></td><td><p>0.09 (0.22)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td><p>-0.55</p><p>(‑1.04, ‑0.06)</p></td><td><p>-0.44</p><p>(‑0.94, ‑0.06)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="3"><p>60</p></td><td><p>‑0.5 (2.8)</p></td><td><p>‑0.4 (3.2)</p></td><td><p>‑0.3 (3.2)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td><p>-0.48 (0.20)</p></td><td><p>-0.54 (0.21)</p></td><td><p>‑0.24 (0.20)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td><p>-0.24</p><p>(‑0.72, 0.24)</p></td><td><p>-0.29</p><p>(‑0.79, 0.20)</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><sup>A</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LS mean, CI and p‑value based on an MMRM with baseline best corrected visual acuity (BCVA) measurement as covariate, treatment group as factor, visit and stratification variables used for randomisation (geographical region, categorical baseline BCVA) as fixed factors as well as terms for the interaction between baseline BCVA and visit and for the interaction between treatment and visit.</p><p><sup>B</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute difference is Eylea 8Q12‑ or 8Q16‑groups minus 2Q8‑groups, respectively.</p><p>CI:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidence interval</p><p>LS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Least square</p><p>SD:&nbsp;&nbsp;&nbsp;&nbsp; Standard deviation</p><p>SE: &nbsp;&nbsp;&nbsp;&nbsp; Standard error</p><p>&nbsp;</p><p><strong>Figure&nbsp;1: LS mean change in central retinal thickness (CRT) from baseline through week&nbsp;60 (full analysis set) in the PULSAR study</strong><!--[if gte vml 1]><v:group
 id="Gruppieren_x0020_34" o:spid="_x0000_s1035" style='position:absolute;
 margin-left:2.55pt;margin-top:26.4pt;width:275.2pt;height:189.6pt;z-index:251658245;
 mso-position-horizontal-relative:text;mso-position-vertical-relative:text;
 mso-width-relative:margin;mso-height-relative:margin' coordsize="34959,24095"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textfeld_x0020_13" o:spid="_x0000_s1036" type="#_x0000_t202"
  style='position:absolute;left:22863;top:21618;width:12096;height:2477;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>weeks<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Textfeld_x0020_30" o:spid="_x0000_s1037" type="#_x0000_t202"
  style='position:absolute;left:-8855;top:8855;width:22948;height:5238;
  rotation:-90;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>LS mean change in CRT (microns)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:anchorlock/>
</v:group><![endif]--><img width="370" height="255" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p><strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Grafik_x0020_45" o:spid="_x0000_i1028" type="#_x0000_t75"
 style='width:453.5pt;height:207.5pt;visibility:visible;mso-wrap-style:square'
 o:bordertopcolor="yellow pure" o:borderleftcolor="yellow pure"
 o:borderbottomcolor="yellow pure" o:borderrightcolor="yellow pure">
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg"
  o:title=""/>
 <w:bordertop type="single" width="6"/>
 <w:borderleft type="single" width="6"/>
 <w:borderbottom type="single" width="6"/>
 <w:borderright type="single" width="6"/>
</v:shape><![endif]--><img width="606" height="278" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg" /></strong></p><p><strong>&nbsp;</strong></p><p><em><u>DME</u></em></p><p><em>&nbsp;</em></p><p>Diabetic macular oedema is characterised by increased vasopermeability and damage to the retinal capillaries which may result in loss of visual acuity.</p><p><em>&nbsp;</em></p><p>The pharmacodynamic effects of aflibercept 114.3&nbsp;mg/ml administered every 12 (8Q12) and every 16 (8Q16) weeks are described in comparison with aflibercept 40&nbsp;mg/ml administered every 8&nbsp;weeks (2Q8) for the DME indication. These effects are shown as the change in the leakage area from baseline to weeks&nbsp;48 and 60.</p><p>&nbsp;</p><p><strong>Table&nbsp;3</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-GB style='mso-bidi-font-size:11.0pt'><span
style='mso-element:field-begin'></span><span style='mso-spacerun:yes'>  </span></span></b><![endif]--><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--><strong>: Pharmacodynamic parameter (full analysis set) in the PHOTON study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td><p><strong>Efficacy Outcomes</strong></p></td><td><p><strong>Week</strong></p></td><td><p><strong>Eylea 8Q12</strong></p><p><strong>(N&nbsp;=&nbsp;328)</strong></p></td><td><p><strong>Eylea 8Q16</strong></p><p><strong>(N&nbsp;=&nbsp;163)</strong></p></td><td><p><strong>Eylea 2Q8</strong></p><p><strong>(N&nbsp;=&nbsp;167)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Change in leakage area from baseline [mm<sup>2</sup>] </strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td><p>48</p></td><td><p>‑13.9 (13.91)</p></td><td><p>‑9.4 (11.50)</p></td><td><p>‑9.2 (12.11)</p></td></tr><tr><td><p>60</p></td><td><p>‑13.9 (13.54)</p></td><td><p>‑12.0 (13.26)</p></td><td><p>‑14.4 (12.89)</p></td></tr></tbody></table><p>SD:&nbsp;&nbsp;&nbsp;&nbsp; Standard deviation</p><p>&nbsp;</p><p><strong>Figure&nbsp;2: LS mean change in central retinal thickness (CRT) from baseline through week&nbsp;60 (full analysis set) in the PHOTON study</strong><!--[if gte vml 1]><v:group
 id="Gruppieren_x0020_33" o:spid="_x0000_s1032" style='position:absolute;
 margin-left:2.55pt;margin-top:31.95pt;width:274.35pt;height:185.95pt;
 z-index:251658244;mso-position-horizontal-relative:text;
 mso-position-vertical-relative:text;mso-width-relative:margin;
 mso-height-relative:margin' coordsize="34864,23618" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Textfeld_x0020_12" o:spid="_x0000_s1033" type="#_x0000_t202"
  style='position:absolute;left:22767;top:21142;width:12097;height:2476;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBLiSFjwgAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9Ni8Iw
EL0L/ocwC9403YIi1ShSkF3EPai9eJttxrZsM6lN1Lq/3giCt3m8z5kvO1OLK7WusqzgcxSBIM6t
rrhQkB3WwykI55E11pZJwZ0cLBf93hwTbW+8o+veFyKEsEtQQel9k0jp8pIMupFtiAN3sq1BH2Bb
SN3iLYSbWsZRNJEGKw4NJTaUlpT/7S9GwSZd/+DuNzbT/zr92p5WzTk7jpUafHSrGQhPnX+LX+5v
HebH8PwlHCAXDwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBLiSFjwgAAANsAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>weeks<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Textfeld_x0020_25" o:spid="_x0000_s1034" type="#_x0000_t202"
  style='position:absolute;left:-8855;top:8855;width:22948;height:5238;
  rotation:-90;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBgXVlTxQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
FMTvBb/D8oTe6sZAi6auIoKkPfRgFPT4mn1NUrNvQ3bNn376rlDocZiZ3zCrzWBq0VHrKssK5rMI
BHFudcWFgtNx/7QA4TyyxtoyKRjJwWY9eVhhom3PB+oyX4gAYZeggtL7JpHS5SUZdDPbEAfvy7YG
fZBtIXWLfYCbWsZR9CINVhwWSmxoV1J+zW5Gwbdxn8vFD83P23Q08Ud2ad5Tq9TjdNi+gvA0+P/w
X/tNK4if4f4l/AC5/gUAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBgXVlTxQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>LS mean change in CRT (microns)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:anchorlock/>
</v:group><![endif]--><img width="369" height="251" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p><!--[if gte vml 1]><v:shape
 id="Grafik_x0020_47" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:453.5pt;
 height:209pt;visibility:visible;mso-wrap-style:square' o:bordertopcolor="yellow pure"
 o:borderleftcolor="yellow pure" o:borderbottomcolor="yellow pure"
 o:borderrightcolor="yellow pure">
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
  o:title=""/>
 <w:bordertop type="single" width="6"/>
 <w:borderleft type="single" width="6"/>
 <w:borderbottom type="single" width="6"/>
 <w:borderright type="single" width="6"/>
</v:shape><![endif]--><img width="606" height="280" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p>After dosing with Eylea&nbsp;114.3&nbsp;mg/ml for up to 48&nbsp;weeks treatment‑emergent antibodies to Eylea&nbsp;114.3&nbsp;mg/ml were detected in 1.2% to 3.8% of patients treated for DME and nAMD. No evidence of anti‑drug antibodies impact on pharmacokinetics, efficacy or safety was observed.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>nAMD</u></em></p><p><em>&nbsp;</em></p><p><em>Study objectives</em></p><p>The safety and efficacy of Eylea&nbsp;114.3&nbsp;mg/ml were assessed in a randomised, multi‑centre, double‑masked, active‑controlled study (PULSAR) in patients with treatment na&iuml;ve nAMD.</p><p>&nbsp;</p><p>The primary objective was to determine if treatment with Eylea&nbsp;114.3&nbsp;mg/ml at intervals of&nbsp;12 (8Q12) or 16&nbsp;weeks (8Q16) provides non‑inferior best corrected visual acuity (BCVA) change compared to Eylea&nbsp;40&nbsp;mg/ml every 8&nbsp;weeks in patients with nAMD.</p><p>The secondary objectives were to determine the effect of Eylea&nbsp;114.3&nbsp;mg/ml versus Eylea&nbsp;40&nbsp;mg/ml on anatomic and other visual measures of response, and to evaluate the safety, immunogenicity, and pharmacokinetics of aflibercept.</p><p>&nbsp;</p><p>The primary efficacy endpoint was the change from baseline in BCVA measured by the early treatment diabetic retinopathy study (ETDRS) letter score at week&nbsp;48.</p><p>The key secondary endpoints were the change in BCVA from baseline at week&nbsp;60 and the proportion of patients with no intraretinal fluid (IRF) and no subretinal fluid (SRF) in central subfield at week&nbsp;16.</p><p>Further secondary endpoints were the proportion of patients gaining at least 15&nbsp;letters in BCVA from baseline at week&nbsp;48, the proportion of patients achieving an ETDRS letter score of at least&nbsp;69 (approximate 20/40 Snellen equivalent) at week&nbsp;48, and the change from baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) total score at week&nbsp;48, among others.</p><p>&nbsp;</p><p>In the PULSAR study a total of 1&nbsp;009&nbsp;patients were treated. The patients were assigned in a 1:1:1 ratio to&nbsp;1 of&nbsp;3 parallel treatment groups:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;114.3&nbsp;mg/ml administered every 12&nbsp;weeks (8Q12)</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;114.3&nbsp;mg/ml administered every 16&nbsp;weeks (8Q16)</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;40&nbsp;mg/ml administered every 8&nbsp;weeks (2Q8)</p><p>&nbsp;</p><p>All patients received 3&nbsp;initial injections of the assigned dose at 4‑week intervals.</p><p>Per study protocol the interval of the 8Q12‑ and 8Q16‑groups was to be shortened if both of the following criteria were met:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;5&nbsp;letters loss in BCVA from week&nbsp;12, and</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;25&nbsp;microns increase in CRT from week&nbsp;12 or new foveal haemorrhage or new foveal neovascularisation.</p><p>&nbsp;</p><p>Regardless of whether patient intervals were maintained or shortened in year&nbsp;1, per study protocol all patients in the 8Q12‑ and 8Q16‑groups were eligible for interval extension (by 4&nbsp;weeks increments), beginning at week&nbsp;52, if the following criteria were met:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;5&nbsp;letters loss in BCVA from week&nbsp;12, and</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; no fluid in the central subfield on optical coherence tomography (OCT), and</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; no new onset of foveal haemorrhage or foveal neovascularisation.</p><p>&nbsp;</p><p>For patients who did not meet the criteria for shortening or extension of the interval, the dosing interval was maintained. The minimum interval between injections was 8&nbsp;weeks in all groups.</p><p>Patients with bilateral disease were eligible to receive Eylea&nbsp;40&nbsp;mg/ml treatment or another anti‑VEGF medicinal product in their fellow eye.</p><p>&nbsp;</p><p><em>Patient characteristics at baseline</em></p><p>Patient ages ranged from 50&nbsp;to&nbsp;96&nbsp;years with a mean of 74.5&nbsp;years.</p><p>Approximately 92% (309/335) and 87% (295/338) of the patients randomised to the 8Q12‑ and 8Q16‑groups, respectively, were 65&nbsp;years of age or older and approximately 51% (172/335) and 51% (171/338) were 75&nbsp;years of age or older.</p><p>&nbsp;</p><p><em>Results</em></p><p>Patients in the 8Q12‑, 8Q16‑ and 2Q8‑groups who completed week&nbsp;48 received a median (mean) of 6.0 (6.1), 5.0 (5.2) and 7.0 (6.9) injections, respectively.</p><p>At week&nbsp;48, in the 8Q12‑group, 79.4% of patients maintained Q12 intervals while in the 8Q16‑group 76.6% of patients maintained Q16 intervals.</p><p>Patients in the 8Q12‑, 8Q16‑ and 2Q8‑groups who completed week&nbsp;60 received a median (mean) of 7.0 (7.1), 6.0 (6.2) and 9.0 (8.8) injections, respectively.</p><p>At week&nbsp;60, 43.1% of patients in the 8Q12‑group were extended to a dosing interval of 16&nbsp;weeks, and 38.5% of patients in the 8Q16‑group were extended to a dosing interval of 20&nbsp;weeks.</p><p>&nbsp;</p><p>Treatment with 8Q12 and 8Q16 was shown to be non‑inferior and clinically equivalent to treatment with 2Q8 in terms of the primary efficacy endpoint &lsquo;mean change in BCVA at week&nbsp;48&rsquo; and the key secondary efficacy endpoint &lsquo;mean change in BCVA at week&nbsp;60&rsquo;.</p><p>&nbsp;</p><p>Furthermore, treatment with Eylea (pooled 8Q12‑ and 8Q16‑groups) was shown to be superior to treatment with 2Q8 in terms of the key secondary efficacy endpoint &lsquo;proportion of patients with no intraretinal fluid (IRF) and no subretinal fluid (SRF) in the central subfield at week&nbsp;16&rsquo; (see table&nbsp;4).</p><p>&nbsp;</p><p><strong>Table&nbsp;4: Efficacy outcomes from the PULSAR study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td><p><strong>Efficacy outcomes</strong></p></td><td><p><strong>Week</strong></p></td><td><p><strong>Eylea 8Q12</strong></p><p><strong>(N&nbsp;=&nbsp;335)</strong></p></td><td><p><strong>Eylea 8Q16</strong></p><p><strong>(N&nbsp;=&nbsp;338)</strong></p></td><td><p><strong>Eylea 2Q8</strong></p><p><strong>(N&nbsp;=&nbsp;336)</strong></p></td></tr><tr><td colspan="5"><p><strong>Change in BCVA from baseline as measured by ETDRS letter score <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="4"><p>48</p></td><td style="vertical-align:top"><p>6.7 (12.6)</p></td><td style="vertical-align:top"><p>6.2 (11.7)</p></td><td style="vertical-align:top"><p>7.6 (12.2)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td style="vertical-align:top"><p>6.06 (0.77)</p></td><td style="vertical-align:top"><p>5.89 (0.72)</p></td><td style="vertical-align:top"><p>7.03 (0.74)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td style="vertical-align:top"><p>-0.97</p><p>(‑2.87, 0.92)</p></td><td style="vertical-align:top"><p>-1.14</p><p>(‑2.97, 0.69)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value (one‑sided non‑inferiority test at a margin of 4&nbsp;letters) <sup>A,B</sup></p></td><td><p>0.0009</p></td><td><p>0.0011</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="4"><p>60</p></td><td style="vertical-align:top"><p>6.6 (13.6)</p></td><td style="vertical-align:top"><p>6.6 (11.7)</p></td><td style="vertical-align:top"><p>7.8 (12.6)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td style="vertical-align:top"><p>6.37 (0.74)</p></td><td style="vertical-align:top"><p>6.31 (0.66)</p></td><td style="vertical-align:top"><p>7.23 (0.68)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td style="vertical-align:top"><p>-0.86</p><p>(‑2.57, 0.84)</p></td><td style="vertical-align:top"><p>-0.92</p><p>(‑2.51, 0.66)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value (one‑sided non‑inferiority test at a margin of 4&nbsp;letters) <sup>A,B</sup></p></td><td><p>0.0002</p></td><td><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Patients with no IRF and no SRF in the central subfield <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="3"><p>16</p></td><td colspan="2" style="vertical-align:top"><p>63.3%</p></td><td style="vertical-align:top"><p>51.6%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td colspan="2"><p>11.7% (5.3%, 18.2%)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value (one‑sided superiority test) <sup>B, C</sup></p></td><td colspan="2"><p>0.0002</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>48</p></td><td style="vertical-align:top"><p>71.1%</p></td><td style="vertical-align:top"><p>66.8%</p></td><td style="vertical-align:top"><p>59.4%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>11.7%</p><p>(4.5%, 18.9%)</p></td><td style="vertical-align:top"><p>7.5%</p><p>(0.1%, 14.8%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>60</p></td><td style="vertical-align:top"><p>74.6%</p></td><td style="vertical-align:top"><p>72.2%</p></td><td style="vertical-align:top"><p>74.6%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>0.0%</p><p>(‑6.6%, 6.7%)</p></td><td style="vertical-align:top"><p>‑2.2%</p><p>(‑8.9%, 4.4%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Patients achieving an ETDRS letter score of at least&nbsp;69 (approximate 20/40&nbsp;Snellen equivalent) <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>48</p></td><td style="vertical-align:top"><p>56.9%</p></td><td style="vertical-align:top"><p>54.3%</p></td><td style="vertical-align:top"><p>57.9%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>‑0.2%</p><p>(‑6.6%, 6.2%)</p></td><td style="vertical-align:top"><p>‑2.2%</p><p>(‑8.4%, 4.0%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>60</p></td><td style="vertical-align:top"><p>56.3%</p></td><td style="vertical-align:top"><p>54.6%</p></td><td style="vertical-align:top"><p>58.2%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>‑1.1%</p><p>(‑7.5%, 5.3%)</p></td><td style="vertical-align:top"><p>‑2.3%</p><p>(‑8.7%, 4.1%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Patients who gained at least 15&nbsp;letters in BCVA from baseline <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>48</p></td><td style="vertical-align:top"><p>20.7%</p></td><td style="vertical-align:top"><p>21.7%</p></td><td style="vertical-align:top"><p>22.1%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>‑1.7%</p><p>(‑7.8%, 4.3%)</p></td><td style="vertical-align:top"><p>‑0.9%</p><p>(‑7.0%, 5.1%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>60</p></td><td style="vertical-align:top"><p>23.7%</p></td><td style="vertical-align:top"><p>23.1%</p></td><td style="vertical-align:top"><p>23.3%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>0.1%</p><p>(‑6.2%, 6.3%)</p></td><td style="vertical-align:top"><p>‑0.7%</p><p>(‑6.9%, 5.5%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>A</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LS mean, CI and p‑value based on an MMRM with baseline best corrected visual acuity (BCVA) measurement as covariate, treatment group as factor, visit and stratification variables used for randomisation (geographical region, categorical baseline BCVA) as fixed factors as well as terms for the interaction between baseline BCVA and visit and for the interaction between treatment and visit.</p><p><sup>B</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute difference is Eylea 8Q12‑ or 8Q16‑groups minus 2Q8‑groups, respectively.</p><p><sup>C</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mantel‑Haenszel weighted treatment difference with stratification variables used for randomization (geographical region, categorical baseline BCVA) and CI calculated using normal approximation.</p><p><sup>D</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Full analysis set</p><p>CI:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidence interval</p><p>LOCF: Last observation carried forward</p><p>LS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Least square</p><p>SD:&nbsp;&nbsp;&nbsp;&nbsp; Standard deviation</p><p>SE: &nbsp;&nbsp;&nbsp;&nbsp; Standard error</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="Gruppieren_x0020_32" o:spid="_x0000_s1029"
 style='position:absolute;margin-left:2.45pt;margin-top:29.45pt;width:276.65pt;
 height:173.15pt;z-index:251658243;mso-width-relative:margin;
 mso-height-relative:margin' coordsize="35150,22020" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Textfeld_x0020_11" o:spid="_x0000_s1030" type="#_x0000_t202"
  style='position:absolute;left:23053;top:19544;width:12097;height:2476;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>weeks<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Textfeld_x0020_17" o:spid="_x0000_s1031" type="#_x0000_t202"
  style='position:absolute;left:-7760;top:7760;width:20758;height:5238;
  rotation:-90;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>LS mean change visual acuity<o:p></o:p></span></p>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>(letters)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:anchorlock/>
</v:group><![endif]--><img width="371" height="233" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><strong>Figure&nbsp;3: LS mean change in BCVA as measured by ETDRS letter score from baseline through week&nbsp;60 (full analysis set) in the PULSAR study</strong></p><p><strong><!--[if gte vml 1]><v:shape id="Grafik_x0020_49"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:453.5pt;height:198.5pt;
 visibility:visible;mso-wrap-style:square' o:bordertopcolor="yellow pure"
 o:borderleftcolor="yellow pure" o:borderbottomcolor="yellow pure"
 o:borderrightcolor="yellow pure">
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image008.jpg"
  o:title=""/>
 <w:bordertop type="single" width="6"/>
 <w:borderleft type="single" width="6"/>
 <w:borderbottom type="single" width="6"/>
 <w:borderright type="single" width="6"/>
</v:shape><![endif]--><img width="606" height="266" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image009.jpg" /></strong></p><p>&nbsp;</p><p>Aflibercept at all doses (8Q12, 8Q16, 2Q8) demonstrated meaningful increase from baseline in the pre‑specified secondary efficacy endpoint national eye institute visual function questionnaire (NEI VFQ‑25).</p><p>No clinically meaningful differences were found between the 8Q12‑, 8Q16‑ and 2Q8‑groups in changes of NEI VFQ‑25 total score at week&nbsp;48 from baseline.</p><p>&nbsp;</p><p>Efficacy results in evaluable subgroups for age, gender, geographic region, ethnicity, race, baseline BCVA, and lesion type were consistent with the results in the overall population.</p><p>Efficacy was generally maintained through week&nbsp;60.</p><p>&nbsp;</p><p><em><u>DME</u></em></p><p>&nbsp;</p><p><em>Study objectives</em></p><p>The safety and efficacy of Eylea&nbsp;114.3&nbsp;mg/ml were assessed in a randomised, multi‑centre, double‑masked, active‑controlled study (PHOTON) in patients with DME.</p><p>&nbsp;</p><p>The primary objective was to determine if treatment with Eylea&nbsp;114.3&nbsp;mg/ml at intervals of&nbsp;12 (8Q12) or 16&nbsp;weeks (8Q16) provides non‑inferior BCVA change compared to Eylea&nbsp;40&nbsp;mg/ml every 8&nbsp;weeks.</p><p>The secondary objectives were to determine the effect of Eylea&nbsp;114.3&nbsp;mg/ml versus Eylea&nbsp;40&nbsp;mg/ml on anatomic and other visual measures of response, and to evaluate the safety, immunogenicity, and pharmacokinetics of aflibercept.</p><p><em>&nbsp;</em></p><p>The primary efficacy endpoint was the change from baseline in BCVA measured by the early treatment diabetic retinopathy study (ETDRS) letter score at week&nbsp;48.</p><p>One key secondary endpoint was the change in BCVA from baseline at week&nbsp;60.</p><p>Further secondary endpoints were the proportion of patients gaining at least 15&nbsp;letters in BCVA from baseline at week&nbsp;48, the proportion of patients achieving an ETDRS letter score of at least&nbsp;69 (approximate 20/40 Snellen equivalent) at week&nbsp;48, and the change from baseline in National Eye Institute Visual Functioning Questionnaire‑25 (NEI‑VFQ‑25) total score at week&nbsp;48, among others.</p><p>&nbsp;</p><p>In the PHOTON study a total of 658&nbsp;patients were treated. The patients were assigned in a 2:1:1 ratio to&nbsp;1 of&nbsp;3 parallel treatment groups:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;114.3&nbsp;mg/ml administered every 12&nbsp;weeks (8Q12)</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;114.3&nbsp;mg/ml administered every 16&nbsp;weeks (8Q16)</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eylea&nbsp;40&nbsp;mg/ml administered every 8&nbsp;weeks (2Q8)</p><p>&nbsp;</p><p>All patients in the 8Q12‑ and 8Q16‑groups received 3&nbsp;initial injections and all patients in the 2Q8‑group received 5&nbsp;initial injections at 4‑week intervals.</p><p>Per study protocol the interval of the 8Q12‑ and 8Q16‑groups was to be shortened if both of the following criteria were met:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;10&nbsp;letter loss in BCVA from week&nbsp;12 in association with persistent or worsening DME, and</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;50&nbsp;microns increase in CRT from week&nbsp;12.</p><p>&nbsp;</p><p>Regardless of whether patient intervals were maintained or shortened in year&nbsp;1, per study protocol all patients in the 8Q12‑ and 8Q16‑groups were eligible for interval extension (by 4&nbsp;weeks increments), beginning at week&nbsp;52, if the following criteria were met:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;5&nbsp;letter loss in BCVA from week&nbsp;12, and</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CRT &lt;300&nbsp;microns on SD‑OCT (or &lt;320&nbsp;microns if measured including RPE).</p><p>&nbsp;</p><p>For patients who did not meet the criteria for shortening or extension of the interval, the dosing interval was maintained. The minimum interval between injections was 8&nbsp;weeks in all groups.</p><p>Patients with bilateral disease were eligible to receive Eylea&nbsp;40&nbsp;mg/ml treatment in their fellow eye.</p><p><em>&nbsp;</em></p><p><em>Patient characteristics at baseline</em></p><p>Patient ages ranged from 24&nbsp;to&nbsp;90&nbsp;years with a mean of 62.3&nbsp;years.</p><p>Approximately 44% (143/328) and 44% (71/163) of the patients randomised to the 8Q12‑ and 8Q16‑groups, respectively, were 65&nbsp;years of age or older and approximately 11% (36/328) and 14% (14/163) were 75&nbsp;years of age or older.</p><p>The proportion of patients who were treated previously for DME was balanced between the treatment groups (43.6% in 8Q12‑, 43.6% in 8Q16‑, 44.3% in 2Q8‑group).</p><p>&nbsp;</p><p><em>Results</em></p><p>Patients in the 8Q12‑, 8Q16‑ and 2Q8‑groups who completed week&nbsp;48 received a median (mean) of 6.0 (6.0), 5.0 (5.0) and 8.0 (7.9) injections, respectively.</p><p>At week&nbsp;48, in the 8Q12‑group, 91.0% of patients maintained Q12 intervals while in the 8Q16‑group 89.1% of patients maintained Q16 intervals.</p><p>Patients in the 8Q12‑, 8Q16‑ and 2Q8‑groups who completed week&nbsp;60 received a median (mean) of 7.0 (7.0), 6.0 (6.0) and 10.0 (9.8) injections, respectively. At week&nbsp;60, 42.6% of patients in the 8Q12‑group were extended to a dosing interval of 16&nbsp;weeks, and 34.2% of patients in the 8Q16‑group were extended to a dosing interval of 20&nbsp;weeks.</p><p>&nbsp;</p><p>Treatment with Eylea (both 8Q12‑ and 8Q16‑groups) was shown to be non‑inferior and clinically equivalent to treatment with 2Q8 in terms of the primary efficacy endpoint &lsquo;mean change in BCVA at week&nbsp;48&rsquo; and the key secondary efficacy endpoint &lsquo;mean change in BCVA at week&nbsp;60&rsquo;.</p><p>&nbsp;</p><p><strong>Table&nbsp;5: Efficacy outcomes from the PHOTON study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td><p><strong>Efficacy outcomes</strong></p></td><td><p><strong>Week</strong></p></td><td><p><strong>Eylea 8Q12</strong></p><p><strong>(N&nbsp;=&nbsp;328)</strong></p></td><td><p><strong>Eylea 8Q16</strong></p><p><strong>(N&nbsp;=&nbsp;163)</strong></p></td><td><p><strong>Eylea 2Q8</strong></p><p><strong>(N&nbsp;=&nbsp;167)</strong></p></td></tr><tr><td colspan="5"><p><strong>Change in BCVA from baseline as measured by ETDRS letter score <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="4"><p>48</p></td><td><p>8.77 (8.95)</p></td><td><p>7.86 (8.38)</p></td><td><p>9.21 (8.99)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td><p>8.10 (0.61)</p></td><td><p>7.23 (0.71)</p></td><td><p>8.67 (0.73)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td><p>‑0.57</p><p>(‑2.26, 1.13)</p></td><td><p>‑1.44</p><p>(‑3.27, 0.39)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value (one‑sided non‑inferiority test at a margin of 4&nbsp;letters) <sup>A,B</sup></p></td><td><p>&lt;0.0001</p></td><td><p>0.0031</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arithmetic mean (SD), observed</p></td><td rowspan="4"><p>60</p></td><td><p>9.05 (9.27)</p></td><td><p>7.96 (9.14)</p></td><td><p>9.62 (9.58)</p></td></tr><tr><td style="vertical-align:top"><p>LS mean (SE) <sup>A</sup></p></td><td><p>8.52 (0.63)</p></td><td><p>7.64 (0.75)</p></td><td><p>9.40 (0.77)</p></td></tr><tr><td style="vertical-align:top"><p>Difference in LS means</p><p>(95% CI) <sup>A,B</sup></p></td><td><p>‑0.88</p><p>(‑2.67, 0.91)</p></td><td><p>‑1.76</p><p>(‑3.71, 0.19)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p‑value (one‑sided non‑inferiority test at a margin of 4&nbsp;letters) <sup>A,B</sup></p></td><td><p>0.0003</p></td><td><p>0.0122</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Patients achieving an ETDRS letter score of at least&nbsp;69 (approximate 20/40 Snellen equivalent) <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>48</p></td><td style="vertical-align:top"><p>65.3%</p></td><td style="vertical-align:top"><p>62.6%</p></td><td style="vertical-align:top"><p>63.0%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>2.45%</p><p>(‑6.47%, 11.36%)</p></td><td style="vertical-align:top"><p>‑0.67%</p><p>(‑11.16%, 9.82%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>60</p></td><td style="vertical-align:top"><p>64.7%</p></td><td style="vertical-align:top"><p>62.0%</p></td><td style="vertical-align:top"><p>60.6%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>4.34%</p><p>(‑4.72%, 13.40%)</p></td><td style="vertical-align:top"><p>1.63%</p><p>(‑8.91%, 12.17%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Patients who gained at least 15&nbsp;letters in BCVA from baseline <sup>D</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>48</p></td><td style="vertical-align:top"><p>18.7%</p></td><td style="vertical-align:top"><p>16.6%</p></td><td style="vertical-align:top"><p>23.0%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>‑4.64%</p><p>(‑12.30%, 3.02%)</p></td><td style="vertical-align:top"><p>‑7.14%</p><p>(‑15.45%, 1.17%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Proportion (LOCF)</p></td><td rowspan="2"><p>60</p></td><td style="vertical-align:top"><p>21.5%</p></td><td style="vertical-align:top"><p>16.0%</p></td><td style="vertical-align:top"><p>26.1%</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted difference in proportion</p><p>(95% CI) <sup>B,C</sup></p></td><td style="vertical-align:top"><p>‑5.01%</p><p>(‑13.04%, 3.02%)</p></td><td style="vertical-align:top"><p>‑10.78%</p><p>(‑19.27%, ‑2.29%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>A</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LS mean, CI and p‑value based on an MMRM with baseline best corrected visual acuity (BCVA) measurement as covariate, treatment group as factor, visit and stratification variables used for randomisation (geographical region, categorical baseline BCVA) as fixed factors as well as terms for the interaction between baseline BCVA and visit and for the interaction between treatment and visit.</p><p><sup>B</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute difference is Eylea 8Q12‑ or 8Q16‑groups minus 2Q8‑groups, respectively.</p><p><sup>C</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mantel‑Haenszel weighted treatment difference with stratification variables used for randomization (geographical region, categorical baseline BCVA) and CI calculated using normal approximation.</p><p><sup>D</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Full analysis set</p><p>CI:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidence interval</p><p>LOCF: Last observation carried forward</p><p>LS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Least square</p><p>SD:&nbsp;&nbsp;&nbsp;&nbsp; Standard deviation</p><p>SE: &nbsp;&nbsp;&nbsp;&nbsp; Standard error</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="Gruppieren_x0020_31" o:spid="_x0000_s1026"
 style='position:absolute;margin-left:1.1pt;margin-top:30.2pt;width:278.35pt;
 height:175.8pt;z-index:251658242;mso-width-relative:margin;
 mso-height-relative:margin' coordsize="35339,22375" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Textfeld_x0020_10" o:spid="_x0000_s1027" type="#_x0000_t202"
  style='position:absolute;left:23242;top:19898;width:12097;height:2477;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>weeks<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Textfeld_x0020_14" o:spid="_x0000_s1028" type="#_x0000_t202"
  style='position:absolute;left:-7762;top:7762;width:20761;height:5238;
  rotation:-90;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f" strokeweight=".5pt">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>LS mean change visual acuity<o:p></o:p></span></p>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
     lang=EN-GB style='font-size:10.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>(letters)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:anchorlock/>
</v:group><![endif]--><img width="374" height="237" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" /><strong>Figure&nbsp;4: LS mean change in BCVA as measured by ETDRS letter score from baseline through week&nbsp;60 (full analysis set) in the PHOTON study</strong></p><p><!--[if gte vml 1]><v:shape
 id="Grafik_x0020_50" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:453.5pt;
 height:199pt;visibility:visible;mso-wrap-style:square' o:bordertopcolor="yellow pure"
 o:borderleftcolor="yellow pure" o:borderbottomcolor="yellow pure"
 o:borderrightcolor="yellow pure">
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image011.jpg"
  o:title=""/>
 <w:bordertop type="single" width="6"/>
 <w:borderleft type="single" width="6"/>
 <w:borderbottom type="single" width="6"/>
 <w:borderright type="single" width="6"/>
</v:shape><![endif]--><img width="606" height="267" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image012.jpg" /></p><p>&nbsp;</p><p>Eylea at all doses (8Q12, 8Q16, 2Q8) demonstrated meaningful increase from baseline in the pre‑specified secondary efficacy endpoint national eye institute visual function questionnaire (NEI VFQ‑25).</p><p>No clinically meaningful differences were found between the 8Q12‑, 8Q16‑ and 2Q8‑groups in changes of NEI VFQ‑25 total score at week&nbsp;48 from baseline.</p><p>&nbsp;</p><p>Efficacy results in evaluable subgroups for age, gender, geographic region, ethnicity, race, baseline BCVA and baseline CRT and prior DME treatment were consistent with the results in the overall population.</p><p>Efficacy was generally maintained through week&nbsp;60.</p><p>&nbsp;</p><p>Treatment effects in the sub‑group of previously treated patients were similar to those seen in patients who were treatment na&iuml;ve.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with aflibercept in all subsets of the paediatric population in nAMD and DME (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption / Distribution</u></p><p>&nbsp;</p><p>Aflibercept is slowly absorbed from the eye into the systemic circulation after intravitreal administration and is predominately observed in the systemic circulation as an inactive, stable complex with VEGF; however only &ldquo;free aflibercept&rdquo; is able to bind endogenous VEGF.</p><p>&nbsp;</p><p>Following unilateral intravitreal administration of 8&nbsp;mg aflibercept, the mean (SD) C<sub>max</sub> of free aflibercept in plasma was 0.25 (0.21) mg/l, and the median time to maximal concentration in plasma was 1&nbsp;day, in the nAMD and DME population combined. The accumulation of free aflibercept in plasma following 3&nbsp;initial monthly doses was minimal. Subsequently, no further accumulation was observed. These data are also supported by population pharmacokinetic analyses.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Aflibercept is a protein‑based therapeutic and no metabolism studies have been conducted.</p><p>&nbsp;</p><p>Aflibercept is expected to undergo elimination through both target‑mediated disposition via binding to free endogenous VEGF and metabolism via proteolysis. The median time to reach the last quantifiable concentration of free aflibercept in plasma for 8&nbsp;mg administered intravitreally was 3&nbsp;weeks.</p><p>&nbsp;</p><p><u>Renal</u><u> or hepatic impairment</u></p><p>&nbsp;</p><p>No special studies in patients with renal or hepatic impairment have been conducted with Eylea&nbsp;114.3&nbsp;mg/ml.</p><p>&nbsp;</p><p>The systemic exposures to aflibercept in patients with mild to severe renal impairment were similar to those with normal renal function. Limited available data in patients with mild hepatic impairment do not indicate an influence on systemic exposures to aflibercept compared to patients with normal hepatic function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Erosions and ulcerations of the respiratory epithelium in nasal turbinates in monkeys treated with aflibercept intravitreally were observed at systemic exposures in excess of the maximum human exposure. The systemic exposure for free aflibercept was approximately 26‑ and 33‑fold higher based on C<sub>max</sub> and AUC when compared to corresponding values in adult patients after an intravitreal dose of 8&nbsp;mg. At the No Observed Adverse Effect Level (NOAEL) of 0.5&nbsp;mg/eye in monkeys the systemic exposure was 3.2‑ and 3.8‑fold higher based on C<sub>max</sub> and AUC when compared to corresponding values in adult patients.</p><p>&nbsp;</p><p>No studies have been conducted on the mutagenic or carcinogenic potential of aflibercept.</p><p>&nbsp;</p><p>An effect of aflibercept on intrauterine development was shown in embryo‑foetal development studies in pregnant rabbits with intravenous (3&nbsp;to&nbsp;60&nbsp;mg/kg) as well as subcutaneous (0.1&nbsp;to&nbsp;1&nbsp;mg/kg) administration. The maternal NOAEL was at the dose of 3&nbsp;mg/kg or 1&nbsp;mg/kg, respectively. A developmental NOAEL was not identified. At the 0.1&nbsp;mg/kg dose, the systemic exposure for free aflibercept was approximately 1.0‑ and 1.0‑fold based on C<sub>max</sub> and cumulative AUC when compared to corresponding values in adult patients after an intravitreal dose of 8&nbsp;mg.</p><p>&nbsp;</p><p>Effects on male and female fertility were assessed as part of a 6‑month study in monkeys with intravenous administration of aflibercept at doses ranging from 3&nbsp;to&nbsp;30&nbsp;mg/kg. Absent or irregular menses associated with alterations in female reproductive hormone levels and changes in sperm morphology and motility were observed at all dose levels. Based on C<sub>max</sub> and AUC for free aflibercept observed at the 3&nbsp;mg/kg intravenous dose, the systemic exposures were approximately 377‑fold and 104‑fold higher, respectively, than the exposure in humans after an intravitreal dose of 8&nbsp;mg. All changes were reversible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose</p><p>Arginine hydrochloride</p><p>Histidine hydrochloride monohydrate</p><p>Histidine</p><p>Polysorbate&nbsp;20</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C&nbsp;&ndash;&nbsp;8&nbsp;&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vial (type&nbsp;I&nbsp;glass) with a grey rubber stopper (chlorobutyl) sealed with an aluminium cap with white lid, and a 18&nbsp;G, 5‑micron&nbsp;filter needle.</p><p>Each vial contains 0.263&nbsp;ml solution.</p><p>Pack size of 1&nbsp;vial and 1&nbsp;filter needle.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The vial is for single use in one eye only. Extraction of multiple doses from a single vial may increase the risk of contamination and subsequent infection.</p><p>&nbsp;</p><p>Do not use if the package or its components are expired, damaged, or have been tampered with.</p><p>Check the label on the vial to make sure you have the strength of Eylea that you intended to use. The 8&nbsp;mg dose requires use of the Eylea&nbsp;114.3&nbsp;mg/ml vial.</p><p>&nbsp;</p><p><u>18&nbsp;G, 5‑</u>micron f<u>ilter needle:</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BD blunt filter (fill) needle, not for skin injection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not autoclave BD blunt filter (fill) needle.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The filter needle is non‑pyrogenic. Do not use it if individual packaging is damaged.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discard the used BD Blunt Filter (Fill) Needle in approved sharps collector.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution: Re‑use of the filter needle may lead to infection or other illness/injury.</p><p>&nbsp;</p><p>The intravitreal injection should be performed with a 30&nbsp;G&nbsp;&times;&nbsp;&frac12;&nbsp;inch injection needle (not included).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>1.</p></td><td colspan="2" style="vertical-align:top"><p>Prior to administration visually inspect the solution for injection.</p><p>Do not use the vial if particulates, cloudiness, or discolouration are visible.</p></td></tr><tr><td style="vertical-align:top"><p>2.</p></td><td style="vertical-align:top"><p>Remove the plastic cap and disinfect the outer part of the rubber stopper of the vial.</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Grafik_x0020_18" o:spid="_x0000_i1031" type="#_x0000_t75"
   style='width:170pt;height:155pt;visibility:visible;mso-wrap-style:square'
   o:bordertopcolor="#ffa500 pure" o:borderleftcolor="#ffa500 pure"
   o:borderbottomcolor="#ffa500 pure" o:borderrightcolor="#ffa500 pure">
   <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
    o:title="584125579__Web"/>
   <w:bordertop type="single" width="4"/>
   <w:borderleft type="single" width="4"/>
   <w:borderbottom type="single" width="4"/>
   <w:borderright type="single" width="4"/>
  </v:shape><![endif]--><img width="228" height="208" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>3.</p></td><td style="vertical-align:top"><p>Use aseptic technique to carry out steps 3‑10.</p><p>Attach the filter needle supplied in the carton to a 1‑ml sterile, Luer‑lock syringe.</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Grafik_x0020_19"
   o:spid="_x0000_i1030" type="#_x0000_t75" style='width:170pt;height:157.5pt;
   visibility:visible;mso-wrap-style:square' o:bordertopcolor="#ffa500 pure"
   o:borderleftcolor="#ffa500 pure" o:borderbottomcolor="#ffa500 pure"
   o:borderrightcolor="#ffa500 pure">
   <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
    o:title="584127243__Web"/>
   <w:bordertop type="single" width="4"/>
   <w:borderleft type="single" width="4"/>
   <w:borderbottom type="single" width="4"/>
   <w:borderright type="single" width="4"/>
  </v:shape><![endif]--><img width="228" height="211" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>4.</p></td><td colspan="2" style="vertical-align:top"><p>Push the filter needle into the centre of the vial stopper until the needle is completely inserted into the vial and the tip touches the bottom or bottom edge of the vial.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>5.</p></td><td colspan="2" style="vertical-align:top"><p>Withdraw all of the Eylea vial content into the syringe, keeping the vial in an upright position, slightly inclined to ease complete withdrawal. To deter the introduction of air, ensure the bevel of the filter needle is submerged into the liquid. Continue to tilt the vial during withdrawal keeping the bevel of the filter needle submerged in the liquid.</p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Grafik_x0020_20"
   o:spid="_x0000_i1029" type="#_x0000_t75" style='width:170pt;height:151.5pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
    o:title="584128907__Web"/>
  </v:shape><![endif]--><img width="227" height="202" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Gruppieren_x0020_7" o:spid="_x0000_s1030" style='position:absolute;
   margin-left:4.45pt;margin-top:121.55pt;width:162.6pt;height:27pt;z-index:251658241;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="20651,3426" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
    <v:stroke joinstyle="miter"/>
    <v:path gradientshapeok="t" o:connecttype="rect"/>
   </v:shapetype><v:shape id="Textfeld_x0020_5" o:spid="_x0000_s1031" type="#_x0000_t202"
    style='position:absolute;left:13811;width:6840;height:3329;visibility:visible;
    mso-wrap-style:square;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
       style='font-size:9.0pt;mso-bidi-font-size:8.0pt'>needle bevel pointing
       down<o:p></o:p></span></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:shape><v:shape id="Textfeld_x0020_4" o:spid="_x0000_s1032" type="#_x0000_t202"
    style='position:absolute;top:1047;width:4439;height:2379;visibility:visible;
    mso-wrap-style:square;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="white [3201]" stroked="f" strokeweight=".5pt">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
       style='font-size:9.0pt;mso-bidi-font-size:8.0pt'>solution<o:p></o:p></span></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:shape></v:group><![endif]--><img width="219" height="39" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[if gte vml 1]><v:shape id="Grafik_x0020_3"
   o:spid="_x0000_i1028" type="#_x0000_t75" style='width:170pt;height:151.5pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image008.png"
    o:title=""/>
  </v:shape><![endif]--><img width="227" height="202" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" /></p></td></tr><tr><td style="vertical-align:top"><p>6.</p></td><td colspan="2" style="vertical-align:top"><p>Ensure that the plunger rod is drawn sufficiently back when emptying the vial to completely empty the filter needle. After injection any unused product must be discarded.</p></td></tr><tr><td style="vertical-align:top"><p>7.</p></td><td colspan="2" style="vertical-align:top"><p>Remove the filter needle and properly dispose of it.</p><p><strong>Note: </strong>The filter needle is <strong>not</strong> to be used for the intravitreal injection.</p></td></tr><tr><td style="vertical-align:top"><p>8.</p></td><td style="vertical-align:top"><p>Firmly twist the 30&nbsp;G&nbsp;&times;&nbsp;&frac12;&nbsp;inch injection needle onto the Luer‑lock syringe tip.</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Grafik_x0020_22"
   o:spid="_x0000_i1027" type="#_x0000_t75" style='width:170pt;height:160.5pt;
   visibility:visible;mso-wrap-style:square' o:bordertopcolor="#ffa500 pure"
   o:borderleftcolor="#ffa500 pure" o:borderbottomcolor="#ffa500 pure"
   o:borderrightcolor="#ffa500 pure">
   <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image010.jpg"
    o:title="584132235__Web"/>
   <w:bordertop type="single" width="4"/>
   <w:borderleft type="single" width="4"/>
   <w:borderbottom type="single" width="4"/>
   <w:borderright type="single" width="4"/>
  </v:shape><![endif]--><img width="228" height="215" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image011.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>9.</p></td><td style="vertical-align:top"><p>Holding the syringe with the needle pointing up, check the syringe for bubbles. If there are bubbles, gently tap the syringe with your finger until the bubbles rise to the top.</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Grafik_x0020_23"
   o:spid="_x0000_i1026" type="#_x0000_t75" style='width:170pt;height:2in;
   visibility:visible;mso-wrap-style:square' o:bordertopcolor="#ffa500 pure"
   o:borderleftcolor="#ffa500 pure" o:borderbottomcolor="#ffa500 pure"
   o:borderrightcolor="#ffa500 pure">
   <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image012.png"
    o:title="584133899__Web"/>
   <w:bordertop type="single" width="4"/>
   <w:borderleft type="single" width="4"/>
   <w:borderbottom type="single" width="4"/>
   <w:borderright type="single" width="4"/>
  </v:shape><![endif]--><img width="228" height="193" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image013.jpg" /></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>10.</p></td><td colspan="2" style="vertical-align:top"><p>To eliminate all bubbles and to expel excess medicinal product, slowly depress the plunger so that the flat plunger edge aligns with the line that marks <strong>0.07&nbsp;ml</strong> on the syringe.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><!--[if gte vml 1]><v:group
   id="Gruppieren_x0020_26" o:spid="_x0000_s1026" style='position:absolute;
   margin-left:190.3pt;margin-top:-.55pt;width:209.75pt;height:154.75pt;
   z-index:251658240;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text;mso-width-relative:margin;
   mso-height-relative:margin' coordsize="26655,19651" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAVxS9qj0EAAA2FAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWNtu4zYQfS/QfyD0vjElWYptrLJI
0iYoEGSDOIt9pinKFkqRKkk7zn5Nv6Vf1kNKshO3u4umlwUKI0gy0oyGM2eGZyi9fbdtJNkIY2ut
iig+oRERiuuyVssi+vBw9WYSEeuYKpnUShTRk7DRu7Pvv3vLZkvD2lXNCTwoO2NFtHKunY1Glq9E
w+yJboWCrtKmYQ6XZjkqDXuE50aOEkrzUcNqFZ3tXf3AHCNrU7/CldT8Z1FeMrVhFi4lnz2/08co
+d/3zGZqc23aeXtnfOT8dnNnSF0WEZBTrAFE0ahX9Ga4HB08tdw72Fam8fa6qsi2iNLTNE5y+Hoq
oizJ8iylnT+xdYTDIMnzdJJkEeGwiKcwwEW34ur9V3zw1Y9f8YJAu4AgPAsyiD7Kz+Se5EPy12bd
trUwQhHc/NZIdDj2CL7IPsvS0z2G8eTUx/qZ7G3bpf7HmseoQ1f0B9SnErIkuDVk7e2J215olC3u
/avN4MX2HXTQADGNk3j6IvCh9DGKnY77sPMkmaZhrV3UbNYa666FbogXisgI7sL+Ypsb67oEB5OQ
kr6qpQzhSkUeiyhPMxoeUIMGzqUKyAzxuu084OETK5+8mwX+I1OjsSQCty2/qrH+DbPujhkQA26C
Ytx7/Kmkxjpc1m1EVtp8Orzn7bBJoYnIIwimiOwva2ZERORPygZXbhDMICwGQa2bSy092j6KIGJt
4+QgVkY3H7Upz/0qUDHFsRYCcma4uHS4hgq8xcX5eZC5blrmbtS8BYPEASGP48P2IzNtD7ZDmW71
fMVa8WeYd7Yd6udrp6u6L0iHnldI6+buSYpQkICxb6CGmZsQBIR7LwRTH4oXkOads2TDfNYpDa0e
arbXX4jq0HIww9N77XnlvmDXax1boJW8HSTSapQkzSkdYyMwucQIkX2jD4YIpm90458yyEgyP1yE
enN9gTp9KqIp4vZKUVXo2K5VAQdztSLuqRUV4+DVh7oRltyKR3KvG6Yi0jKlLRQ0wU9OU5rRMX4T
SGNoa8dXV6yppSdKjDG+YsaKUPeAsGD/mnMkjUQDSmdWy7XDdCWscsIQsW2FlBiChNWGLNaLhURW
GLDQcGEtaURZ81oxib7S5Zo7T0tA3PsMIKnS76r750B+mHdAxvH/EEmxSziAgI3hAdmxz9qKeXuP
vun4raMnWHSs/QXu3s2sPXfvJ5Zn6b/M3WAN9No4zykIvOuxft5OExpPfQ/6sU7jMU36bTKw/0DL
R+Y+MveO2ffcvOP4I3P7OfHfMHeJ6UJA1cKfBQg9oae//drIIx0P8+cfpeMEZ7aDozRuBRLFO9ar
6Dihp9nEH9H9AYBmyeTwXQovARRMHFh5Gidp9vIt4HiePp6n+zEtn523j6z8Tc/TFd4LSCvXaulP
0+VSHAn51YSMY3L/aWd08MUscHv/hc9/lnt+ffY7AAAA//8DAFBLAwQUAAYACAAAACEAkn2H4B0H
AABJIAAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2xZL1iI3Jg
yXLcxC9ESoocKYnaZcxdLkjKjm5FcuqlQIG06KEBeuuhKBqgARr00h9jwEGb/ogOuS9SouIHXCAo
bAHG7uw3w+HM7Mzs8M7dZxH1jjEXhMVtv3qr4ns4HrExiYO2/2iw/dlt3xMSxWNEWYzb/gwL/+7G
p5/cQesjSpIhQ3w8CHGEPRAUi3XU9kMpk/WVFTECMhK3WIJjeDZhPEISbnmwMuboBBaI6MpqpdJc
iRCJ/Q2QKJWgHoV/sRSKMKK8r8RgL0YRrH4wmZAR1tjxUVUhxEx0KfeOEW37IHPMTgb4mfQ9ioSE
B22/ov/8lY07K2g9Y6JyCa/Bt63/Mr6MYXy0qtfkwbBYtF5v1JubhXwNoHIR12v1mr1mIU8D0GgE
O011sWW2Vrv1DGuA0kuH7K3WVq1q4Q35tQWdNxvqZ+E1KJVfX8Bvb3fBihZeg1J8YwHf6Kx1tmz5
GpTimwv4VmVzq96y5GtQSEl8tICuNJq1br7bAjJhdMcJX2vUt1urmfASBdFQRJdaYsJiuSzWIvSU
8W0AKCBFksSenCV4gkYQk11EyZATb5cEIQRegmImgFxZrWxXavBf/er6SnsUrWNkcCu9QBOxQFL6
eGLESSLb/n2Q6huQs7dvT5+/OX3+++mLF6fPf83W1qIsvh0UBybf+5+++efVl97fv/34/uW36dLz
eGHi3/3y1bs//vyQeNhxaYqz716/e/P67Puv//r5pUP6JkdDEz4gERbePj7xHrIINujQHw/55TgG
ISImx2YcCBQjtYpDfk+GFnp/hihy4DrYtuNjDqnGBbw3fWop3A/5VBKHxAdhZAH3GKMdxp1WeKDW
Msw8mMaBe3E+NXEPETp2rd1FseXl3jSBHEtcIrshttQ8pCiWKMAxlp56xo4wduzuCSGWXffIiDPB
JtJ7QrwOIk6TDMjQiqaSaYdE4JeZS0Hwt2Wbvcdeh1HXrrfwsY2EdwNRh/IDTC0z3kNTiSKXyAGK
qGnwXSRDl5L9GR+ZuJ6Q4OkAU+b1xlgIF88Bh/0aTn8Aacbt9j06i2wkl+TIJXMXMWYit9hRN0RR
4sL2SRya2M/FEYQo8g6ZdMH3mP2GqHvwA4qXuvsxwZa7z88GjyDDmiqVAaKeTLnDl/cws+K3P6MT
hF2pZpNHVord5MQZHZ1pYIX2LsYUnaAxxt6jzx0adFhi2bxU+n4IWWUHuwLrPrJjVd3HWGBPNzeL
eXKXCCtk+zhgS/TZm80lnhmKI8SXSd4Hr5s270Gpi1wBcEBHRyZwn0C/B/HiNMqBABlGcC+Vehgi
q4Cpe+GO1xm3/HeRdwzey6eWGhd4L4EHX5oHErvJ80HbDBC1FigDZoCgy3ClW2Cx3F+yqOKq2aZO
von90pZugO7IanoiEp/bAc31Po3/rveBDuPsh1eOl+16+h23YCtZXbLTWZZMdub6m2W4+a6my/iY
fPxNzRaaxocY6shixrrpaW56Gv9/39Mse59vOpll/cZNJ+NDh3HTyWTDlevpZMrmBfoaNfBIBz16
7BMtnfpMCKV9OaN4V+jBj4DvmfE2EBWfnm7iYgqYhHCpyhwsYOECjjSPx5n8gsiwH6IEpkNVXwkJ
RCY6EF7CBAyNNNkpW+HpNNpj43TYWa2qwWZaWQWSJb3SKOgwqJIputkqB3iFeK1toAetuQKK9zJK
GIvZStQcSrRyojKSHuuC0RxK6J1dixZrDi1uK/G5qxa0ANUKr8AHtwef6W2/UQcWYIJ5HDTnY+Wn
1NW5d7Uzr9PTy4xpRQA02HkElJ5eU7ou3Z7aXRpqF/C0pYQRbrYS2jK6wRMhfAZn0amoF1Hjsr5e
K11qqadModeD0CrVaN3+kBZX9TXwzecGGpuZgsbeSdtv1hoQMiOUtP0JDI3hMkogdoT65kI0gOOW
keTpC3+VzJJwIbeQCFOD66STZoOISMw9SqK2r7ZfuIHGOodo3aqrkBA+WuXWIK18bMqB020n48kE
j6TpdoOiLJ3eQoZPc4XzqWa/Olhxsim4ux+OT7whnfKHCEKs0aoqA46JgLODamrNMYHDsCKRlfE3
V5iytGueRukYSumIJiHKKoqZzFO4TuWFOvqusIFxl+0ZDGqYJCuEw0AVWNOoVjUtqkaqw9Kqez6T
spyRNMuaaWUVVTXdWcxaIS8Dc7a8WpE3tMpNDDnNrPBp6p5PuWt5rpvrE4oqAQYv7OeouhcoCIZq
5WKWakrjxTSscnZGtWtHvsFzVLtIkTCyfjMXO2e3okY4lwPilSo/8M1HLZAmeV+pLe062N5DiTcM
qm0fDpdhOPgMruB42gfaqqKtKhpcwZkzlIv0oLjtZxc5BZ6nlAJTyym1HFPPKfWc0sgpjZzSzClN
39MnqnCKrw5TfS8/MIUalh2wZr2Fffq/8S8AAAD//wMAUEsDBBQABgAIAAAAIQCcZkZBuwAAACQB
AAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzhI/NCsIwEITv
gu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR7Nsb6EVB8LIws+w3s037sjN5YkyTdxxqWgFBp7yenOFw
6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKUxikkUigucRhzDifGkhrRykR9QFc2g49W5iKjYUGquzTI
9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/thmBSevXpYdPlHBMulFxagjAYzB0pXZ501LV2BiYZ9/Sbe
AAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAAAAAAAAAAAAAAAAAAABbQ29u
dGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAAAAAAAAAA
NgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAFcUvao9BAAANhQAAB8AAAAAAAAAAAAAAAAA
IAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQSwECLQAUAAYACAAAACEAkn2H4B0H
AABJIAAAGgAAAAAAAAAAAAAAAACaBgAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWxQSwECLQAU
AAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAAAAAAAAAAAAAADvDQAAY2xpcGJvYXJkL2RyYXdpbmdz
L19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAFAAUAZwEAAPIOAAAAAA==
">
   <v:shape id="Textfeld_x0020_15" o:spid="_x0000_s1027" type="#_x0000_t202"
    style='position:absolute;left:10121;width:16534;height:6229;visibility:visible;
    mso-wrap-style:square;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f" strokeweight=".5pt">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
       style='font-size:9.0pt;mso-bidi-font-size:8.0pt'>solution after
       expelling air bubbles and excess medicinal product<o:p></o:p></span></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:shape><v:shape id="Textfeld_x0020_16" o:spid="_x0000_s1028" type="#_x0000_t202"
    style='position:absolute;top:4660;width:9201;height:5014;visibility:visible;
    mso-wrap-style:square;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f" strokeweight=".5pt">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
       style='font-size:9.0pt;mso-bidi-font-size:8.0pt'>dose line for
       0.07&nbsp;ml<o:p></o:p></span></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:shape><v:shape id="Textfeld_x0020_21" o:spid="_x0000_s1029" type="#_x0000_t202"
    style='position:absolute;left:20758;top:10528;width:5530;height:9123;
    visibility:visible;mso-wrap-style:square;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f" strokeweight=".5pt">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
       style='font-size:9.0pt;mso-bidi-font-size:8.0pt'>flat plunger edge<o:p></o:p></span></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:shape><w:anchorlock/>
  </v:group><![endif]--><img width="283" height="209" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image014.gif" /><!--[if gte vml 1]><v:shape
   id="Grafik_x0020_24" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:406.5pt;
   height:208.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image015.png"
    o:title=""/>
  </v:shape><![endif]--><img width="542" height="278" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image016.gif" /></p></td></tr></tbody></table><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG
51368 Leverkusen
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>